A hydrogel formulation for treating bacterial skin infections
By using Peruvian croton oil filter latex hydrogel formulations, the problem of topical antibiotic resistance has been solved, providing multi-target treatment for bacterial skin infections, especially atopic eczema and impetigo, achieving effective treatment with low systemic absorption.
Patent Information
- Application Number
- CN202280030859.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-05-17
- Filing Date
- 2022-02-25
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-02-25
AI Technical Summary
Existing topical antibiotics such as mupirocin and fusidic acid face resistance problems when treating bacterial skin infections, especially in skin diseases such as atopic eczema and impetigo, where the resistance rate of Staphylococcus aureus is high, making treatment difficult.
Using the filtered latex of Peruvian croton (Müll.Arg. Filtered latex of Peruvian croton) as a hydrogel formulation, containing therapeutically effective amounts of components, it is used for the topical treatment of bacterial skin infections, utilizing the synergistic effect of its multiple bioactive compounds to provide multi-target therapeutic effects.
It effectively combats a variety of bacteria, reduces the risk of drug resistance, and provides a safe topical treatment option. It is suitable for infections of various bacterial skin diseases such as atopic eczema, impetigo, and epidermolysis bullosa, reduces systemic absorption, and improves treatment efficacy.
Smart Images

Figure CN117715651B_ABST
Abstract
Description
[0001] Cross-reference with related applications
[0002] This application claims the interests of U.S. Provisional Application No. 63 / 153,864, filed February 25, 2021, and U.S. Provisional Application No. 63 / 189,276, filed May 17, 2021. The disclosure of each of these applications is incorporated herein by reference. Summary of the Invention
[0003] This invention generally relates to a hydrogel formulation comprising a therapeutically effective amount of Croton lechleri latex, preferably a filtered latex of Croton lechleri, and more preferably a filtered latex of Croton lechleri Müll.Arg., wherein the therapeutically effective amount contains at least the component concentration of a reference standard. The component concentrations and performance standards of the Croton lechleri latex, preferably the filtered latex of Croton lechleri, and preferably the filtered latex of Croton lechleri Müll.Arg. are shown in Tables 1a-e. Attached Figure Description
[0004] Figure 1 Representative total ion chromatograms and additional multiple reaction monitoring spectra were depicted to identify the marker compounds in the AB-101 compositions.
[0005] Figure 2A The NMR spectra of AB-101 in D2O were depicted, with the top spectrum representing batch 00, the middle spectrum representing batch 01, and the bottom spectrum representing batch 02.
[0006] Figure 2B The NMR spectra of batches 00, 01, and 02 of AB-101 in D2O were superimposed.
[0007] Figure 3A Nuclear magnetic resonance (NMR) spectra of three batches of AB-101 in d4-methanol were depicted, with the top spectrum representing batch 00, the middle spectrum representing batch 01, and the bottom spectrum representing batch 02.
[0008] Figure 3B The NMR spectra of batches 00, 01 and 02 of AB-101 in d4-methanol were superimposed.
[0009] Figure 4A NMR spectra of four batches of AB-101 in d4-methanol were depicted. The top spectrum represents batch 00, the upper middle spectrum represents batch 01, the lower middle spectrum represents batch 02, and the bottom spectrum represents batch X.
[0010] Figure 4B The NMR spectra of batches 00, 01, 02 and X of AB-101 in d4-methanol were superimposed.
[0011] Figure 5 The bar charts depict the analytical results of A) gallocatechin, B) epigallocatechin, C) catechin, D) epicatechin, and E) taspine in batch AB-101.
[0012] Figure 6 A representative total ion chromatogram of dimethylcedrusin was depicted.
[0013] Figure 7 A liquid bandage containing a film-forming hydrogel of 50% AB-101 was described.
[0014] Figure 8 The hydrogel with dimethyl silicone oil added after hydrogel formation is depicted.
[0015] Figure 9 The hydrogel with dimethyl silicone oil added before hydrogel formation is depicted.
[0016] Figure 10 Microscopic images depicting the addition of dimethyl silicone oil after hydrogel formation are shown, revealing a brown color, indicating that AB-101 has been trapped in the hydrogel matrix.
[0017] Figure 11 Microscopic images depicting the addition of dimethyl silicone oil prior to hydrogel formation are shown, revealing a blue hue that indicates air has been trapped between AB-101 and the hydrogel matrix.
[0018] Figure 12 The trapping of air in the formulation caused by high shear was described.
[0019] Figure 13 Demulsification was depicted when AB-101 was added to water before hydrogel formation.
[0020] Figure 14 Gel permeation chromatograms of each of the three PMMA standards were depicted.
[0021] Figure 15 The gel permeation chromatograms of three PMMA standards were overlaid.
[0022] Figure 16 A chromatogram of AB-101 batch 01 at a concentration of 1.25 mg / mL was plotted.
[0023] Figure 17A Depicting Mw The calibration curve.
[0024] Figure 17B Depicting M n The calibration curve.
[0025] Figure 18 The results of a batch of AB-101 particle size distribution analysis were presented.
[0026] Figure 19 The mobility distribution of zeta potentials of a batch of drug AB-101 extracts was depicted.
[0027] Figure 20 The mobility distribution of the zeta potential of a batch of AB-101 hydrogels was depicted.
[0028] definition
[0029] Before describing the compositions and methods of the present invention, it should be understood that the invention is not limited to the specific processes, compositions, or methods described, as they are variable. It should also be understood that the terminology used in this specification is for the purpose of describing a particular version or embodiment only and is not intended to limit the scope of the embodiments described herein, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any similar or equivalent methods and materials described herein may be used in the practice or testing of the embodiments described herein, preferred methods, apparatus, and materials will now be described. All publications mentioned herein are incorporated herein by reference in their entirety. Nothing herein should be construed as an admission that the embodiments described herein are not authorized by prior art prior to such disclosure.
[0030] The following terms, as used herein, have the meanings indicated.
[0031] It must also be noted that, when used herein and in the appended claims, the singular form includes the plural references, unless the context clearly specifies otherwise.
[0032] The term “approximately” as used in this article is intended to describe the numerical value it modifies, indicating that the value is a variable within a range of error. When no specific range of error is stated, such as the standard deviation of the mean given in a graph or data table, the term “approximately” should be understood to mean plus or minus 10% of the numerical value used with it. Therefore, approximately 50% means within the range of 45%–55%.
[0033] As used herein, the term "AB-101" may be used interchangeably with latex of *Croton tiglium*, preferably filtered latex of *Croton tiglium*, preferably filtered latex of *Müll. Arg.* *Croton tiglium*, and plant material. The latex is material expelled from the wounded trunk of *Croton tiglium*, preferably *Müll. Arg.* *Croton tiglium*. In all such cases, the latex is whole latex. In all such cases, the latex is unfractionated.
[0034] As used herein, the term "acute bacterial skin or skin structure infection" is defined as a bacterial infection of the skin, including but not limited to bacterial skin infections, drug-resistant bacterial skin infections, or multidrug-resistant bacterial skin infections. Furthermore, such infections may be uncomplicated or concurrent, mild or severe. These infections may be without lesions, abscesses, or wounds (e.g., primary infections such as all forms of impetigo, including but not limited to nemopirox pustulosis) or may have lesions, abscesses, or wounds. Moreover, such infections may be of any size, including those up to 75 cm in diameter. 2 Infection of any larger lesion (often referred to as acute bacterial skin and skin structure infection (or ABSSSI)) or infection of smaller skin lesions (often referred to as secondary infectious traumatic lesion (or SITL), skin and soft tissue infection (or SSTI)).
[0035] When used in conjunction with a therapeutic agent such as AB-101, “application” means the direct application of the therapeutic agent to or onto a target tissue, or the application of the therapeutic agent to a patient, thereby causing the therapeutic agent to have a positive effect on the targeted tissue. Therefore, when used in conjunction with the compositions described herein, the term “application” as used herein may include, but is not limited to, providing the composition to or onto a target tissue, or providing the composition to a patient by, for example, topical application, thereby enabling the therapeutic agent to reach the target tissue. “Application” of the composition may be done topically or in combination with other known techniques.
[0036] As used in this article, the term “cellulitis / erysipelas” is defined as a diffuse bacterial skin infection characterized by a spreading area of redness, edema, and / or induration.
[0037] The transitional term “includes”, which is synonymous with “including,” “containing,” or “characterized in,” is inclusive or open-ended and does not exclude additional undescribed elements or methodological steps.
[0038] In embodiments or claims that use the term "comprising" as a transitional term, it is also contemplated that the term "comprising" in such embodiments may be replaced with the terms "consisting of" or "substantially consisting of".
[0039] As used herein, the term "composed of" means that a hydrogel formulation, pharmaceutical composition, composition, or method includes only the elements, steps, or components specifically described in the particular claimed embodiment or claim.
[0040] As used herein, the term "consistently composed of" means that a hydrogel formulation or method includes only the elements, steps, or components specifically described in the particular claimed embodiment or claim, and may optionally include other elements, steps, or components that do not substantially affect the essential and novel features of the particular embodiment or claim. For example, the only active ingredient in a composition or method for treating a particular condition (e.g., nutritional failure) is the therapeutic agent specifically described in the particular embodiment or claim.
[0041] The term "combination therapy" means administering two or more therapeutic agents to treat the therapeutic condition or disorder described in this disclosure. Such administration includes co-administering these therapeutic agents in a substantially simultaneous manner, for example, in a single capsule having a fixed proportion of the active ingredients or in multiple separate capsules for each active ingredient. Furthermore, such administration also includes using each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide the beneficial effect of the combination of drugs in treating the condition or disorder described herein.
[0042] The term “disease” as used herein is generally synonymous with and interchangeable with the terms “disorder,” “syndrome,” and “symptom” (as in medical conditions) because they all reflect an abnormal condition of the human or animal body or one of its parts that impairs normal function, typically manifested as distinctive signs and symptoms, and resulting in a reduction in lifespan or quality of life in the person or animal.
[0043] The terms “excipient” and “pharmaceuticalally acceptable excipient” as used herein are generally synonymous with and interchangeable with the terms “carrier”, “pharmaceuticalally acceptable carrier”, “diluent”, and “pharmaceuticalally acceptable diluent”.
[0044] As used herein, the term "extract" refers to a liquid that flows between the bark and woody parts of a tree and is, and remains, undistilled.
[0045] As used herein, the term "severe skin abscess" is defined as a bacterial infection characterized by a large accumulation of pus within or deeper into the dermis, accompanied by redness, edema, and / or induration.
[0046] The term "patient" is generally synonymous with the term "subject" and includes all mammals, including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
[0047] As used herein, the term "pharmaceutically acceptable salt" refers to a salt prepared from a base or acid that is acceptable for administration to patients, such as mammals. The term "pharmaceutically acceptable salt" includes salts commonly used to form alkali metal salts and addition salts that form free acids or free bases. The properties of the salt are not critical, as long as it is pharmaceutically acceptable. Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and pharmaceutically acceptable inorganic or organic acids.
[0048] When used in each embodiment of this document, sap may in particular include sap, latex, resin, extract, or any combination of the foregoing substances.
[0049] As used in this article, the terms “therapeutic agent” or “medicinal agent” or “pharmaceutical active agent” mean a medicine used to treat, counteract, improve, prevent or improve an unwanted symptom or disease in a patient.
[0050] The term "therapeuticly acceptable" refers to compositions that are suitable for use in contact with a patient's tissues without excessive toxicity, irritation, or allergic reactions, are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use.
[0051] As used herein, the term "therapeuticly acceptable salt" refers to a salt or zwitterionic form of the compounds disclosed herein, which is soluble or dispersed in water or oil and is therapeutically acceptable as defined herein. The salt may be prepared during the final isolation and purification of the compound, or separately by reacting a suitable compound in free base form with a suitable acid.
[0052] The term "therapeuticly effective" is intended to define the amount of active ingredient used in the treatment of a disease or disorder or in the achievement of a clinical endpoint.
[0053] The "therapeutic effective amount" or "effective amount" of a composition is a predetermined amount calculated to achieve the desired effect (i.e., inhibition, blocking, or reversal of cell activation, migration, or proliferation). The activity contemplated by the methods of the present invention includes, depending on the circumstances, medical therapeutic and / or preventative treatment. Of course, the specific dose of the compound administered according to the present invention to obtain therapeutic and / or preventative effects will be determined by the specific circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated. The compound is effective over a wide dose range; for example, the dose per application is typically in the range of 0.001 to 10 mg / kg, more typically in the range of 0.01 to 1 mg / kg. However, it should be understood that the effective amount administered will be determined by the physician based on relevant circumstances, including the condition to be treated, the choice of the compound to be administered, and the chosen route of administration; therefore, the above dose range is not intended to limit the scope of the invention in any way. The therapeutic effective amount of the compositions of the present invention is generally an amount sufficient to achieve an effective systemic or local concentration in tissues when administered with physiologically tolerable excipient compositions.
[0054] As used herein, the term "treatment" refers to both therapeutic treatment and preventative measures, the purpose of which is to prevent or alleviate (mitigate) an undesirable physical symptom, disorder, or disease, or to achieve a beneficial or desired clinical outcome. For the purposes of this invention, a beneficial or desired clinical outcome includes, but is not limited to, symptom relief, reduction of the severity of the symptom, disorder, or disease, stabilization (i.e., non-deterioration) of the state of the symptom, disorder, or disease, delay of the onset or slowing of the progression of the symptom, disorder, or disease, improvement of the state of the symptom, disorder, or disease, and remission (partial or complete) or promotion or improvement of the symptom, disorder, or disease, whether detectable or undetectable. Treatment includes eliciting a clinically significant response without excessively high levels of side effects. Treatment also includes extending survival compared to expected survival in the absence of treatment. Treatment may also be preemptive in nature, i.e., it may include disease prevention. Disease prevention may involve complete protection against disease, such as in the case of prevention of pathogen infection, or it may involve prevention of disease progression. For example, disease prevention may not mean the complete loss of any effects associated with the disease at any level, but may mean preventing disease symptoms from reaching a clinically significant or detectable level. Disease prevention may also mean preventing the disease from progressing to a later stage.
[0055] The term "local" includes application to or suitability for such application to any skin or mucous membrane surface. In some embodiments, "local" can be a skin surface. Skin surfaces include any part of the body, including but not limited to the face, hands, legs, neck, abdomen, eyes, nose, and chest. Mucous membrane surfaces include but are not limited to the oral mucosa or oral cavity mucosa, lips, tongue, nose, buccal mucosa, palate, gums, nasopharynx, respiratory epithelium, conjunctiva, vagina, cervix, and urethral mucosa.
[0056] As used in this article, the term "wound" is defined as damage to living tissue caused by cutting, striking, or other impact, typically involving cuts or breaks in the skin.
[0057] As used herein, the term “wound infection” is defined as a bacterial infection characterized by purulent drainage from the wound, accompanied by surrounding redness, edema, pain, tenderness, and / or induration.
[0058] Embodiments are also provided in which any of the embodiments described herein may be combined with any or more of the other embodiments, unless otherwise stated, and provided that such combinations are not mutually exclusive. Detailed Implementation
[0059] Plant chemical defenses involve complex mixtures of organic compounds and typically do not involve individual substances; these compounds appear in varying concentrations (majority or minority) in a variety of products derived from natural species. It can be found that the bioactivity of these products derives from their ability to interact with themselves and with other substances through synergistic, additive, and antagonistic effects, and can be optimized by altering the pharmacokinetics and / or pharmacodynamics of the component substances. Biological effects may arise from interactions with all organic compounds or from interactions between certain components that may exist as a majority or minority. Therefore, when described herein, AB101 consists of whole latex obtained from the Peruvian croton tree—which is unfractionated—but selected based on the presence of a chosen component that satisfies the reference standard described herein.
[0060] In natural product research, the role and mechanism of major compounds in their associated biological activities are typically studied. Consequently, countless published studies in the scientific literature have identified major components as responsible for these activities. However, this overlooks the potential interactions between the overall composition of compounds that may exist in natural products at lower concentrations. A study using thyme essential oil and its major component, thymol, showed that the effects of the oil's components were not phytotoxic to lettuce seeds, while the individual effect of thymol significantly inhibited seed germination, suggesting the possibility that thymol activity is partially inhibited by other components of the oil. This demonstrates the importance of considering the interactions between all components of the product.
[0061] For example, the analgesic activity of the sap of *Dracaena cochinchinensis* and three active components was evaluated, the analgesic activity arising from the inhibition of capsaicin-induced currents on TRPV1 channels. As a result, the authors found that the combination of the three active components of the sap caused the analgesic activity of the species under discussion, where these components acted synergistically, since compounds present at higher concentrations did not directly cause the discovered biological activity.
[0062] Another consideration regarding the interactions between the active components of natural products is the ability to alter the pharmacokinetics of these components compared to administration of the molecules alone. This can be achieved by modifying absorption, distribution, metabolism, and elimination properties. One study reported a comparison of the pharmacokinetic properties of chlorogenic acid and coryloin alone with those of DA-9701, a product derived from hydroalcoholic extracts of the tubers of *Ipomoea quamoclit* and *Corydalis yanhusuo* (containing equivalent concentrations of both components). The results showed that the AUC of coryloin was significantly increased when DA-9701 was administered (both orally) compared to administration of either compound alone. This increase in AUC can be explained by reduced first-pass metabolism in the liver and / or gastrointestinal tract compared to pure coryloin. Furthermore, other components of DA-9701 may inhibit the systemic pre-metabolism of corticosteroids.
[0063] Another example is the complexity of metabolic pathways; the complexity of essential oils, extracts, and herbal products may be directly related to the recorded biological effects. In a study of Eucalyptus globulus essential oil and its major components, all three major components were observed to enhance the contractile effect of acetylcholine in the rat trachea, but the essential oil exhibited a relaxing effect upon potassium stimulation, possibly due to inhibition of acetylcholinesterase activity.
[0064] The Peruvian croton (a member of the family Euphorbiaceae (commonly known as the spurge family)) comprises approximately 1300 plant species, taking the form of herbaceous plants (plants without persistent woody stems above ground level), shrubs (woody plants smaller than trees with several main stems growing at or near the ground), trees (perennial plants, most species having slender stems or trunks supporting branches and leaves), or vines (any of various long-stemmed woody vines that take root in the soil at ground level and use trees and other vertical supports to climb the canopy and enter the sunlit areas of the forest). The genus *Croton* is a diverse and complex group of flowering plants, ranging from herbs and shrubs to trees. *Croton* is widely distributed in tropical and subtropical regions worldwide.
[0065] Dragon's blood refers to the bright red resin obtained from different species within several different plant genera: *Croton*, *Dracaena*, *Calamus rotang*, and *Pterocarpus*. This red resin has been used since ancient times as a varnish, medicine, incense, and dye. The name *Dracaena* is used to refer to all of the aforementioned plant genera, usually without distinguishing between the genus or species from which it originates. Plants within the same genus are similar in any therapeutic or nutritional value, with variability and inconsistencies arising from factors such as local soil, rainfall, humidity, sunshine, and fauna. However, the differences between red resins from the *Croton* and *Calamus* genera (*Calamus* palms, Arecaceae family, mainly distributed in tropical and subtropical Southeast Asia, with a few species extending into southern China and the Himalayas) are significant. *Croton* and *Calamus* are native to opposite ends of the world, and therefore their compositions differ; thus, the specificity of the source plant is important for providing the desired medicinal benefits or avoiding adverse toxicity. For example, milky-white latexes that are typically toxic or at least irritating to the skin are common among members of the Euphorbiaceae family. Therefore, in order to obtain latexes with specific and reproducible medicinal properties, it is crucial to select specific genera, species, and local geographical regions of the Euphorbiaceae family.
[0066] Several species of the genus Croton, found in the rainforests of South America (Bolivia, Brazil, Colombia, Ecuador, and Peru), Central America, and Mexico, produce a red latex with medicinal value, commonly known as dragon's blood. Croton trees growing in these regions include Peruvian Croton (Croton lechleri), Croton draco, Croton palanostigma, Croton sordidus, Croton urucurana, and Croton xalapenesis.
[0067] In some embodiments, the specific dragon blood tree used in this application is *Crotonlechleri* Müll.Arg. of the Euphorbiaceae family. *Crotonlechleri* is also known as *Sangre de drago* (Peru) and *Sangre de grado* (Ecuador).
[0068] Although the desired medicinal properties can be obtained by extracting the composition from the leaves or bark, in a preferred embodiment, the deep red latex of Croton tiglium, also known as latex, is used, preferably the filtered latex of Croton tiglium, and more preferably the filtered latex of Müll. Arg. Croton tiglium, wherein the composition contains at least a component concentration of the latex of Croton tiglium as a reference standard, preferably a component concentration of the filtered latex of Croton tiglium, and more preferably a component concentration of the filtered latex of Müll. Arg. Croton tiglium. According to Langenheim (2003), resin “is a fat-soluble mixture of volatile and non-volatile terpenoid and / or phenolic secondary compounds, usually secreted in special structures located inside or on the surface of plants, and potentially important in ecological interactions.” In contrast, latex is a mixture of terpenoids, phenolic compounds, acids, carbohydrates, etc., with protective effects (Lewisohn 1991), and is produced in special cells called latex ducts (Fahn 1979). The chemical characteristics of dragon's blood are species-specific and have been studied by many authors. For example, dragon's blood from certain individual species can be distinguished for use in artworks because it has been sold as a colorant for centuries (Baumer and Dietemann 2010). Dragon's blood from Croton species is often referred to as latex due to its secretion and storage via latex ducts; its main component is polymeric anthocyanins, which coexist with many minor components including diterpenoids and simple phenols (Salatino et al., 2007). Dragon's blood secreted from the stems of medicinal Pterocarpus officinalis is also referred to as latex (Weaver 1997; Guerrero and Guzman 2004); however, little is known about the chemical composition of the exudate and its ecological functions. Dragon's blood from species of the Dracaena and Rattan genera is a phenolic resin (Langenheim 2003) with a well-established chemical composition (e.g., Gonzalez et al., 2000; Shen et al., 2007; Sousa et al., 2008). Sometimes, dragon's blood is referred to as latex (e.g., Philipson 2001). However, this can prove to be a source of confusion, as the plant produces other exudates referred to by that name, such as xylem latex and phloem latex, which are entirely different in location, chemical composition, and function. The resin is obtained by tapping the tree or other common dranining methods. Dredging tree latex has the added advantage of not having to use complex and expensive extraction techniques to obtain the desired composition from the leaves or bark. The latex of *Croton tiglium* (Müll. Arg. Peru) of this application was then filtered through a 30-micron filter to remove plant debris and thick resinous material. The chemical characteristics of dragon's blood are local geography specific and have not been studied by previous authors.
[0069] The medicinal and toxic properties of various species in the genus *Croton* have been attributed to a wide range of compounds, such as terpenes and steroids, alkaloids, and phenols, the latter primarily including flavonoids, lignans, and proanthocyanidins. Certain embodiments of this application utilize whole latex, thereby taking advantage of the “organic” synergistic effect of all latex components intended to be provided by nature. The molecular classes present in the latex of *Croton burmannii* of this application, providing all the medicinal benefits of *Croton burmannii*, are: alkaloids, diterpenes, lignans, phenols, phytosterols, proanthocyanidins, sterols, and tannins.
[0070] Hydrogel formulations require safety properties for topical application, low systemic blood absorption (i.e., entry into the bloodstream) of the composition, and a low partition coefficient, measured by LogP. LogP represents the solute concentration partitioned between the organic and aqueous phases. A low LogP implies a higher partition or concentration of the solute in the aqueous phase, which is ideal from a safety perspective. A higher LogP indicates that the composition is more likely to be absorbed through organs and tissues and retained in the body, while a lower LogP indicates greater safety because the composition will be naturally eliminated without absorption or retention, which could otherwise lead to the accumulation of toxic compounds.
[0071] AB-101 utilizes the unique composition of whole latex from Müll.Arg. Peruvian croton. The novelty of this invention lies in the identification of the pharmaceutical composition AB-101, which possesses all the performance properties listed above for treating skin conditions and promoting healing with suitable safety characteristics. This represents a complex, multivariate solution for optimizing multiple performance properties, a solution that is not apparent to those skilled in the art.
[0072] In the embodiments disclosed herein, the latex of Peruvian croton, preferably filtered latex of Peruvian croton, and preferably filtered latex of Müll.Arg. Peruvian croton, is not fractionated, but contains at least some component concentrations and performance standards of the reference standards listed in Tables 1a-e.
[0073] AB-101 is the first new drug in its class of novel broad-spectrum topical antibiotics known as multi-target therapeutic agents (MTTs). The AB-101 platform utilizes the latex of the Peruvian croton tree (Müll. Arg.), a natural and ubiquitous plant found in the Amazon rainforest. The extract and therefore AB-101 botanical active pharmaceutical ingredient (BDS) contain a variety of bioactive compounds.
[0074] Common skin conditions requiring novel medical solutions include skin and skin structure infections (SSSI), also known as skin and soft tissue infections (SSI) or acute bacterial skin and skin structure infections (ABSSSI). The pathogens involved are most commonly bacterial species, therefore these infections require treatment with antibiotics. These skin infections can be acute or chronic, primary or secondary.
[0075] Some common skin conditions include, but are not limited to, atopic dermatitis (AD), also known as atopic eczema or eczema, impetigo, and infections associated with complications of epidermolysis bullosa (EB). In these cases, bacterial pathogens may be the primary source of the skin condition or associated as a secondary complication. In all cases, topical treatment of the skin condition to address the bacterial pathogen is the focus of AB-101 pharmaceutical-grade compositions.
[0076] The need for more effective antibiotics stems from the problem of bacterial resistance that has emerged with current antibiotic treatments. This is problematic for two of the most commonly used topical antibiotics, mupirocin and fusidic acid. Increased use of mupirocin is prone to leading to resistance, which is significantly associated with persistent MRSA infection. Mupirocin resistance has been reported to be as high as 81% (T. Poovelikunnel et al., Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA, J Antimicrob Chemother 2015;70:2681–2692 doi:10.1093 / jac / dkv169, Advance Access Publication, July 3, 2015). Antibiotic resistance is a significant problem in both hospitals and the community. Topical antibiotics are widely used for skin problems, which may lead to the emergence of drug-resistant bacteria (M Shah et al., High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients, Br JDermatol. 2003 May; 148(5):1018-20. doi:10.1046 / j.1365-2133.2003.05291.x.). Shah showed that 50% of Staphylococcus aureus isolates from dermatology patients were fusidic acid resistant. This figure rises to 78% in patients with atopic eczema. Among patients with fusidic acid-resistant Staphylococcus aureus isolates, 96% had used fusidic acid-containing preparations within the previous 6 months. The fusidic acid resistance level in Staphylococcus aureus samples cultured from non-dermatological patients was only 9.6%, significantly lower than that in dermatological patients (P<0.001).
[0077] Eczema (Infectious and Non-Infectious): Ogonowska's publications (including those of many scholars he cites) elucidate the role of the pathogen Staphylococcus aureus in exacerbating eczema (Ogonowska et al., Colonization with Staphylococcus aureus in Atopic Dermatitis Patients: Attempts to Reveal the Unknown), Frontiers in Microbiology. January 2021. Volume 11. Article 567090. doi:10.3389 / fmicb.2020.567090.eCollection 2020). Some key issues in the treatment of AD / eczema highlighted by Ogonowska include:
[0078] • Chronic and relapsing inflammatory skin disorder. However, it can persist or appear during adolescence and adulthood. AD typically occurs in 15–30% of children and 2–10% of adults worldwide.
[0079] • Patients develop a high prevalence of Staphylococcus aureus in both diseased and non-disease-affected skin. If left untreated, the skin infection can progress to a systemic infection. Interestingly, the incidence of multidrug-resistant Staphylococcus aureus (MRSA) is higher in AD patients compared to healthy individuals, making treatment even more challenging.
[0080] High rates of Staphylococcus aureus colonization were observed in both the pediatric and adult groups. Colonization rates increased with the severity of Alzheimer's disease (AD) and were a contributing factor to worsening inflammation.
[0081] Among Staphylococcus aureus isolates, methicillin-resistant Staphylococcus aureus (MRSA) constitutes an important and significant group requiring particular attention. MRSA is a group of strains resistant to multiple β-lactam antibiotics (cephalosporins, carbapenems, monolactams, and penicillins). This phenotype limits treatment options, including those for skin infections. The percentage of MRSA has been shown to be 4–13 times higher in Staphylococcus aureus strains colonizing patients with Alzheimer's disease compared to healthy individuals.
[0082] • The colonization of MRSA constitutes the most well-known risk of infection. In public places such as gyms, MRSA can be easily transferred through direct skin contact, thereby further spreading the bacteria.
[0083] One of the main factors contributing to the increased susceptibility of Staphylococcus aureus colonization is the alteration of lipid and fatty acid composition in the skin. Significantly lower levels of ceramides and higher levels of cholesterol are observed in the epidermis, particularly the stratum corneum. This decrease in skin lipid levels may explain the role of these components in maintaining skin hydration.
[0084] To restore the proper barrier function of damaged skin, it is essential to maintain the disrupted hydration of the epidermis. Therefore, moisturizing creams containing emollients and humectants have been shown to reduce itching, redness, and even decrease the need for anti-inflammatory medications.
[0085] Impetigo (infectious and non-infectious): Impetigo is the most common bacterial infection in children. This acute, highly contagious superficial infection is primarily caused by *Streptococcus pyogenes* or *Staphylococcus aureus*. Secondary skin infections can also occur from existing skin lesions (e.g., cuts, abrasions, insect bites, chickenpox) (Moulin F, Quinet B, Raymond J, Gillet Y, Cohen R., *Managing children skin and soft tissue infections*, Arch Pediatr. 2008 Oct. 15 Suppl 2:S62-7). These infections include methicillin-resistant Staphylococcus aureus (MRSA) (Moran GJ, Amii RN, Abrahamian FM, Talan DA, Methicillin-resistant Staphylococcus aureus in community-acquired skin infections, Emerg Infect Dis. 2005 Jun. 11(6): 928-30). As shown in the figure below, impetigo is divided into non-bullous (contact-transmitted impetigo) (approximately 70% of cases) or bullous (Cole C, Gazewood J., Diagnosis and treatment of impetigo, Am Fam Physician. 2007 Mar 15. 75(6): 859-64).
[0086] Although topical antibiotics such as mupirocin and fusidic acid are commonly prescribed medications, there is growing concern that they may contribute to antimicrobial resistance.
[0087] Epidermolysis bullosa: EB is a rare, inherited connective tissue disorder affecting 1 in 20,000 newborns in the United States (approximately 200 children are born with EB each year). EB has many genetic and symptomatic variations, but all variations share a common prominent symptom: extremely fragile skin that blisters and tears from even minor friction or trauma. The list of complications and secondary diseases can be long, requiring multiple interventions from a range of medical specialists. EB affects all sexes, races, and ethnic groups equally.
[0088] Patients with epidermolysis bullosa (EB), a hereditary blistering disease, often have chronic wounds that can be colonized by various bacteria, particularly the opportunistic pathogen Staphylococcus aureus. Therefore, we determined the colonization rate of Staphylococcus aureus in swabs collected from the anterior nasal cavity, throat, and wounds of EB patients from the Netherlands. Over a period of approximately 2 years, over 90% of chronic wound samples from EB patients were found to be colonized by Staphylococcus aureus. Molecular typing revealed that EB patients were not colonized by a single type of Staphylococcus aureus. Instead, the Staphylococcus aureus population structure in the sampled EB patients reflected the local Staphylococcus aureus population structure in the Netherlands (Magdalena M. van der Kooi Pola et al., Host-pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus, J Med Microbiol. 2014 Mar; 304(2):195-203).
[0089] Although EB is a more severe but more localized skin condition than eczema or impetigo, they share the commonality of needing to fight bacterial infection. Treatment with topical antibiotics, especially those highly effective against Staphylococcus aureus and MRSA (Streptococcus pyogenes), can effectively help treat infections in all three of these life-threatening skin conditions.
[0090] Psoriasis is a skin condition that causes red, itchy, scaly plaques, most commonly affecting the knees, elbows, trunk, and scalp. As defined by the Mayo Clinic, psoriasis is a common, long-term (chronic) condition that is incurable. Most types of psoriasis experience cycles, with flare-ups lasting weeks or months, followed by periods of remission or even symptom relief. The signs and symptoms of psoriasis vary from person to person. Common signs and symptoms include: 1. red plaques of skin covered with dense, silvery scales; 2. small, scaly spots (common in children); 3. dry, cracked skin that may bleed or itch; 4. itching, burning, or pain; 5. thickened, pitted, or raised nails; and 6. swollen and stiff joints. The extent of psoriatic plaques can range from a few dandruff-like scaly spots to large, widespread eruptions. The most commonly affected areas are the lower back, elbows, knees, legs, soles of the feet, scalp, face, and palms.
[0091] As reported by S. Lafi et al., secondary bacterial invasion complicates psoriatic lesions. Such infections can progress rapidly and be life-threatening. Hassan investigated the prevalence of secondary bacterial infections in psoriasis and also highlighted emerging trends associated with antibacterial resistance (Lafi, S., Hasan, A., Al-Alowssi, M., (2010), Secondary Bacterial Infections Complicating Psoriasis, Egyptian Academic Journal of Biological Sciences, G. Microbiology, 2(2), 37-42).
[0092] In another study by Eva Marcus, nearly half of the patients in the study had colonization of pathogenic bacteria in their psoriatic plaques. The examination of the bacterial flora in psoriasis focused on evidence of Staphylococcus aureus, which was found to be prevalent in up to 64% of the affected skin in patients with plaque psoriasis. Correspondingly, Staphylococcus aureus has also been found to be the most prevalent bacterium in patients with recurrent pustular psoriasis. In this study, 31% of the bacteria were Gram-positive and 9% were Gram-negative (Marcus, E., Demmler, D., Rudolph, A. and Fischer, M., (2011), Bacterial colonization of psoriasis plaques. Is it relevant?, Dermatology reports, 3(2)).
[0093] AB-101 is an important topical treatment for alleviating and curing psoriasis symptoms. Staphylococcus aureus is the most common pathogen isolated from psoriatic lesions, and AB-101 has proven highly effective against it. Furthermore, with increasing multidrug resistance, particularly against Staphylococcus aureus, the presence of MRSA is also increasing. Its Gram-negative efficacy also contributes to AB-101's positive effects. The availability of a novel MDR topical treatment for secondary bacterial invasion to prevent fatal systemic infections demonstrates that AB-101 is an excellent antibiotic treatment for psoriasis.
[0094] As detailed by Sunhyo Ryu, pathogen colonization is an important unresolved skin condition (S. Ryu, P.Song, C.Seo, H. Cheong, and Y. Park, Colonization and Infection of the Skin by S. aureus: Immune System Evasion and the Response to Cationic Antimicrobial Peptides, Int. J. Mol. Sci. 2014, 15, 8753-8772). The colonizing pathogens are primarily associated with Staphylococcus aureus and MRSA, and AB-101 is an effective and novel treatment for these pathogens.
[0095] Ryu details the causes, mechanisms, and risks associated with colonized Staphylococcus aureus and MRSA. Specifically, Staphylococcus aureus is a widespread skin pathogen that causes the vast majority of bacterial skin infections in humans. The incidence of Staphylococcus aureus skin infections partly reflects the competition between the host's skin immune defenses and Staphylococcus aureus virulence factors. Staphylococcus aureus can live as a symbiotic organism on the skin, as well as in the nose and throat. Approximately 30% of healthy individuals are asymptomatically colonized by Staphylococcus aureus, permanently colonizing the anterior nasal cavity in 10%–20% of the population, intermittently colonizing in 30%–50% of the population, and the remainder are never colonized. Importantly, this colonization is a known risk factor for infection, and Staphylococcus aureus causes a range of infections from minor skin infections to abscesses, endocarditis, and sepsis, and is also a leading cause of hospital-acquired infections, as colonized healthcare workers can transmit the pathogen to immunocompromised patients. In addition, several cases of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infection have been recently reported. It is noteworthy that these reports describe severe and even fatal infections in immune individuals caused by highly virulent strains of Staphylococcus aureus.
[0096] MRSA infections are caused by strains of Staphylococcus aureus that have developed resistance to antibiotics commonly used to treat common infections. Most MRSA infections occur in people already admitted to hospitals or other healthcare facilities such as nursing homes and dialysis centers. When it occurs in these settings, it is called healthcare-associated MRSA (HA-MRSA). HA-MRSA infections are often associated with invasive procedures or devices such as surgery, intravenous catheterization, or artificial joints. However, another type of MRSA infection occurs in the wider community, between otherwise healthy individuals. This form of community-associated MRSA (CA-MRSA) is transmitted through skin-to-skin contact. It usually begins as a painful boil and typically causes skin and soft tissue infections, but it can also cause invasive diseases such as endocarditis, necrotizing pneumonia, and sepsis. In contrast, HA-MRSA is considered a hospital-acquired pathogen, which is typically associated with invasive diseases such as blood infections, pneumonia, surgical site infections, and urinary tract infections.
[0097] AB-101 and its MTT are novel and critical antibiotics for addressing the colonization of Staphylococcus aureus and MRSA, as they are associated with obstruction of the nasal or ear canal caused by Staphylococcus aureus and MRSA. They are also used as preoperative cleansing agents to prevent SSTI or sepsis in any other application known to those skilled in the art, applications related to conditions that can prevent the spread and elimination of colonizing Staphylococcus aureus and MRSA.
[0098] AB-101 is an effective treatment for wounds (including superficial cuts / lacerations and abrasions) and chronic infections. Chronic infections and wounds include, but are not limited to, diabetic ulcers, arterial ulcers, venous ulcers, mixed arterial and venous ulcers, and pressure sores. Those familiar with these infections and wounds, as well as those skilled in the art, know that they are caused by Gram-positive pathogens associated with Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, and Gram-negative pathogens such as Pseudomonas aeruginosa. Furthermore, chronic wounds are highly complex and difficult to heal. Killing bacteria is a key element in achieving the healing process. The fact that AB-101 is effective against both Gram-positive and Gram-negative pathogens, along with its MTT (meta-to-triple) properties, provides a unique therapeutic effect for this pharmaceutical compound.
[0099] In summary, AB-101 is the first new drug in its class of novel broad-spectrum topical antibiotics known as multi-target therapeutic agents (MTTs). The AB-101 plant-derived active pharmaceutical ingredient (BDS) extract contains a variety of bioactive compounds, making it an ideal and highly effective antibiotic for treating local skin infections. The indications against which AB-101 is effective, along with a summary of the associated pathogens causing SSTIs and wound infections, and a detailed disease overview, are shown in Table A.
[0100] Table A
[0101]
[0102] *For those skilled in the art, including but not limited to
[0103] AB-101 has been shown to possess a unique safety profile, unexpectedly maximizing drug delivery while simultaneously enhancing safety based on its physical properties. This unexpected finding contradicts common understanding among those skilled in the art. The general practice, for those skilled, is to formulate a safe and effective drug at the lowest possible dose while providing the desired therapeutic effect. The opposite is true for AB-101. By maximizing dose delivery, safety is also synergistically maximized. This is due to the fact that any lipophilic component of AB-101 is likely to be absorbed through the skin, leaving only the hydrophilic component available for blood absorption. This results in any AB-101 absorbed into the bloodstream being naturally and easily eliminated through normal bodily functions. Systemic absorption is also negligible, thus reducing any safety risks. This makes AB-101 a very potent and extremely effective antibiotic designed to treat topical SSTIs.
[0104] Some embodiments of this document relate to a method for identifying a latex composition of croton tiglium, preferably a filtered latex composition of croton tiglium, and preferably a filtered latex composition of croton tiglium (Müll. Arg.), the method comprising: (a) determining the component concentration of the croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of croton tiglium (Müll. Arg.); (b) comparing the component concentration with the component concentration of a reference standard; and (c) identifying the croton tiglium latex composition, preferably the filtered latex composition of croton tiglium, and preferably the filtered latex composition of croton tiglium (Müll. Arg.), wherein the composition contains at least the component concentration of the croton tiglium latex of the reference standard, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of croton tiglium (Müll. Arg.).
[0105] Some embodiments of this document relate to a method for identifying a latex composition of croton tiglium, preferably a filtered latex composition of croton tiglium, and preferably a filtered latex composition of croton tiglium (Müll. Arg.) for treating skin conditions in subjects, the method comprising: (a) determining the component concentration of the croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of croton tiglium (Müll. Arg.) for treating skin conditions in subjects; (b) comparing the component concentration with the component concentration of a reference standard; and (c) identifying the croton tiglium latex composition, preferably the filtered latex composition of croton tiglium, and preferably the filtered latex composition of croton tiglium (Müll. Arg.) for treating skin conditions in subjects, wherein the composition contains at least the component concentration of the croton tiglium latex of the reference standard, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of croton tiglium (Müll. Arg.) for treating skin conditions in subjects.
[0106] Some embodiments of this document relate to a method for identifying a latex composition of croton tiglium, preferably a filtered latex composition of croton tiglium, or preferably a filtered latex composition of croton tiglium, for the treatment or prevention of skin conditions or for reducing the risk of skin conditions, the method comprising: (a) determining the component concentration of the croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, or preferably the component concentration of the filtered latex of croton tiglium; (b) comparing the component concentration with the component concentration of a reference standard; and (c) identifying a latex composition of croton tiglium, preferably the filtered latex composition of croton tiglium, or preferably the filtered latex composition of croton tiglium, for the treatment or prevention of skin conditions or for reducing the risk of skin conditions in subjects, wherein the composition contains at least the component concentration of the croton tiglium latex of the reference standard, preferably the component concentration of the filtered latex of croton tiglium, or preferably the component concentration of the filtered latex of croton tiglium.
[0107] In some embodiments, the specific dragon's blood tree used in this application is *Croton tiglium* (Müll. Arg., Euphorbiaceae). *Croton tiglium* is also known as *Sangre de drago* (Peru) or *Sangre de grado* (Ecuador). Embodiments of the invention relate to hydrogel formulations of *Croton tiglium* latex, preferably filtered *Croton tiglium* latex, preferably filtered *Croton tiglium* latex, and pharmaceutically acceptable excipients. Such hydrogel formulations have been found to be effective in treating skin conditions. In some embodiments, the hydrogel formulation is applied topically. In some embodiments, the hydrogel formulation is applied nasally. The embodiments relate to hydrogel formulations comprising a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of the croton tiglium latex of the reference standard disclosed herein, preferably the component concentration of the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of Müll. Arg. croton tiglium) and a pharmaceutically acceptable carrier, and also to methods of manufacturing and using said compounds and compositions. Some embodiments relate to methods of inhibiting skin conditions. Other embodiments relate to methods of treating skin conditions in patients requiring treatment, said methods comprising administering to said patient a therapeutically effective amount of the composition according to the invention. The use of certain croton tiglium extracts disclosed herein in the preparation of medicaments for treating skin conditions is also provided.
[0108] hydrogel formulation
[0109] The embodiments described herein relate to hydrogel formulations comprising latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of Müll.Arg. croton tiglium ( wherein the composition contains at least a component concentration of croton tiglium latex of a reference standard, preferably a component concentration of filtered latex of croton tiglium, and preferably a component concentration of filtered latex of Müll.Arg. croton tiglium).
[0110] The preferred treatment needs to be effective and capable of easily delivering broad-spectrum antibiotic activity, including against Staphylococcus aureus, MRSA, and Streptococcus pyogenes. The antibiotic needs to be easily released from the carrier, which should help retain the active antibiotic ingredient on the skin rather than enhancing skin permeability, which promotes systemic absorption and reduces its safety. The amount of antibiotic should be at a sufficiently high level to achieve complete bacterial kill, thereby minimizing the initiation of antimicrobial resistance. The carrier should moisturize the affected area, helping the skin return to its normal state. In this concept, the delivery system should also function as a liquid bandage to help seal in moisture and protect the injured or affected area. The AB-101 topical antibiotic delivery system has been developed to combine these novel and unexpected performance characteristics in a single product to help promote the healing and resolution of these skin conditions.
[0111] The AB-101 topical antibiotic delivery system utilizes a hydrogel therapeutic carrier and structure, and can be in forms including, but not limited to, ointments, gels, mousses, creams, and sprays. Hydrogels containing AB-101 can be incorporated into dressings, sponges, tapes, patches, or bandages. It can be delivered via, but not limited to, tubing, pumps, cans, manual / mechanical sprays, or aerosol packaging and delivery systems. The hydrogel delivery system is designed to rapidly release the pharmaceutical-grade AB-101 antibiotic at the maximum delivery dose to ensure efficacy and safety. Due to its high water content, the hydrogel is an effective humectant, and the film-forming properties of AB-101, combined with the hydrogel, promote the formation of a liquid bandage.
[0112] AB-101 can be used as a topical antibiotic for treating skin conditions in its full-strength or undiluted form. In this form, AB-101 is thin and fluid. The advantages of converting and formulating AB-101 into a hydrogel offer unexpected new benefits related to performance efficacy, improved safety, improved application, ease of application, enhanced performance of protective liquid bandages, and known hydration benefits.
[0113] Applying AB-101 to maximize efficacy is a key requirement for ensuring optimal performance. To avoid or at least minimize the promotion of antibiotic resistance, eradication of all target bacteria is essential. Specifically, antibiotic dosages are designed to eradicate the entire population of pathogens. When antibiotics are not taken throughout the entire prescribed course, pathogens can adapt to the presence of low doses and eventually develop into a population completely resistant to any dose. This means the hydrogel carrier needs to be designed to contain the highest possible level of pharmaceutical-grade AB-101, which is as thermodynamically stable as possible. This requires formulation expertise from those skilled in the art and extensive experimentation to determine the ideal formulation.
[0114] The final pH of hydrogels containing AB-101 can range from 4.0 to 6.7. This range offers both skin health benefits and antimicrobial benefits.
[0115] All hydrogel components and initial products used with AB-101 formulations must meet the specifications for cosmetic or pharmaceutical-grade carriers suitable for dermatological applications. To ensure gentleness, AB-101 hydrogels do not use more than approximately 2 wt% of monohydric alcohols, including but not limited to methanol, ethanol, propanol, denatured alcohol, and alkoxylated cetyl alcohol. The antibiotic activity of AB-101 hydrogel formulations depends primarily on the level of AB-101 rather than the initial level, with all formulations containing AB-101 levels ranging from 5% to 50%. AB-101 hydrogel formulations do not rely on cromoglycine or its salts as the active ingredient for treating dermatitis. Formulations may also include secondary antibiotic components, as well as ingredients that contribute to improving skin health, which may include, and are limited to, vitamins, emollients, hyaluronic acid, propylene glycol, proteins, and urea to help attract moisture into the skin, and lanolin, mineral oil, and petrolatum to lock in moisture.
[0116] Croton tiglium, Sangre de Drago, or dragon's blood have been used and incorporated into hydrogels. As described in Vasquez's example, the wound-healing effect of Sepigel-based hydrogels on wound healing was investigated. The levels of croton tiglium used ranged from 0.5% to 2%. (Guillermo Jose Gallardo Vasquez, Bach. Laura Barboza Mejia, Healing effect of the gel made from the latex of Croton tiglium "Blood of Drago"), Rev CientCienc Med 2015;18(1):10–16). This gel is unsuitable for eczema. The levels of croton tiglium are too low, and the pH of these formulations is between 6.8 and 6.9. The gel is also formulated with ethanol, which reduces its mildness. Vasquez did not mention antibiotic activity. From an antibiotic perspective, the levels of croton tiglium should be considered initial or ineffective, which is ineffective in eradicating bacterial infections and may lead to antibiotic resistance. A pH level that is too high does not promote the ideal level for skin health and actually creates an environment conducive to the growth of Staphylococcus aureus and MRSA.
[0117] Bobrowski (US 7,883,727) describes the use of Peruvian croton extract CGO 110 as a treatment for vomiting and itching. CGO 110 is depleted of its normal proanthocyanidin components to eliminate the reddish-brown color, thus structurally different from AB-101 by reducing proanthocyanidin levels. CGO 110 is formulated as “Aloe barbadensis gel for topical application to various inflammatory, itchy, and irritating skin conditions.” Aloe barbadensis gel is similar in properties to aloe vera gel and is not considered a hydrogel (https: / / puracy.com / blogs / ingredients / aloe-barbadensis, February 2021). The level of Peruvian croton extract CGO 110 present in the aloe barbadensis gel is less than 2%. The topical gel described by Bobrowski should not be confused with the hydrogel designed for the delivery of AB-101.
[0118] Palacios Peláez et al. (US2019 / 0240193) formulated an aloe vera gel for the treatment of atopic dermatitis skin, in which a surprising synergistic effect was observed between a sodium cromoglycate formulation using alkoxylated cetyl alcohol as a base ingredient and low levels of croton tiglium and panthenol. The croton tiglium used was in the form of a water-diol solution (water and propylene glycol), wherein the croton tiglium had been diluted to 1% to 5% by weight. This solution was further diluted in Peláez's embodiment, resulting in croton tiglium significantly lower than 2% of the total formulation when the composition used the aloe vera gel. This embodiment relied on the synergistic effect of sodium cromoglycate, which was absent in the AB-101 hydrogel composition.
[0119] The pharmaceutical composition AB-101 uses whole latex of Müll. Arg. Peruvian croton. The art is replete with examples of fractionating Müll. Arg. Peruvian croton latex, separating individual components, or minimizing or eliminating individual components. This may be a result of specific applications. For pharmaceutical grade AB-101, it is preferable to use the whole extract to utilize the synergistic effects associated with all active compounds.
[0120] Importantly, the variations in all compounds are quite significant, as indicated by key variables such as geography, environment, soil, altitude, and tree age. Thiago Vaz Lopes, in his update on the chemical composition and medical applications of Dragon's Blood (Müll. Arg. Peruvian Croton), discusses this natural plant extract. These changes are highlighted in "An Update on the Chemical Composition and Medical Applications of This Natural Plant Extract", Revista Brasileira de Higiene and Animal Health (v.7, n2) p.167-192 (2013).
[0121] The novelty of AB-101 is based on identifying the link between a specific compound and its concentration level in AB-101 through bioassays of in vitro efficacy, and confirming its effectiveness as a treatment for wounds, bleeding, and infections through human use trials. The practicality of this discovery forms the basis for developing drugs and pharmaceutical products that meet FDA standards.
[0122] The FDA has established the need for the use of bioassays that, based on the chemical properties of a composition and their variations, correlate the performance of plant-based ingredients with efficacy in wound treatment, bleeding control, and anti-infection.
[0123] The latex of Müll.Arg. Peruvian Croton is complex, difficult, and cannot be defined straightforwardly because its composition uses all the accompanying components of all the bioactive materials that make up the latex of Müll.Arg. Peruvian Croton. New discoveries are needed to find key biomarkers and to test its performance and safety.
[0124] The FDA requires the identification of key biomarkers or active ingredients that drive biological activity. In this regard, the key biomarkers and their associated concentrations of AB-101 related to wound healing properties (wound management, hemostasis, and anti-infection), antimicrobial activity, and therapeutic safety have never been published, defined, or identified. Without this information, the FDA will not grant legal status for the drug to be used medicinally, which is central to its status as a pharmaceutical product.
[0125] "Pharmaceutical products" means any product, compound, drug, or therapeutic agent that is regulated as a drug, pharmaceutical preparation, or controlled substance by a foreign equivalent agency of the U.S. Food and Drug Administration.
[0126] The FDA's guidance on herbal medicines states:
[0127] Due to the heterogeneity of herbal medicines and the potential uncertainty of their active ingredients, one of the key issues is ensuring consistent therapeutic efficacy across batches of marketed drugs. Generally, therapeutic consistency can be supported by an "overall evidence" approach, including considerations such as:
[0128] • Control of plant materials (e.g., agricultural practices and collection).
[0129] • Quality control is achieved through chemical testing (e.g., analytical testing, such as spectroscopic and / or chromatographic methods for capturing the active chemical components of plant-based pharmaceutical ingredients) and production control (e.g., process validation).
[0130] • Bioassays (e.g., bioassays reflecting the known or intended mechanism of action of a drug) and clinical data (details on the use of clinical data to ensure treatment consistency).
[0131] By using the complete latex of Müll. Arg. Peruvian croton, a unique synergistic effect can be achieved throughout the composition, thereby meeting specific bioassay performance targets. Table B shows 16 bioactive substances found in pharmaceutical grade AB-101. These bioactive compounds provide antimicrobial, antiviral, anti-inflammatory, cell proliferation-promoting healing, anticancer, hemostatic, antioxidant, and fibroblast-stimulating-healing effects. Significant synergistic effects in wound healing and infection prevention are achieved by maintaining the integrity of the Müll. Arg. Peruvian croton latex.
[0132] Table B shows the bioactive compounds found in the whole latex of Müll.Arg. Peruvian croton in AB-101 and their properties.
[0133] Table B
[0134]
[0135]
[0136] Some embodiments of this document relate to a hydrogel formulation comprising a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least a component concentration of the reference standard of croton tiglium latex of the embodiments described herein, preferably a component concentration of the filtered latex of croton tiglium ... In some embodiments, the latex of Peruvian croton, preferably filtered latex of Peruvian croton, and preferably filtered latex of Müll.Arg. Peruvian croton has the PDI of the embodiments disclosed herein.
[0137] The embodiments described herein relate to a hydrogel formulation comprising:
[0138] The composition comprises a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of croton tiglium Müll.Arg. croton tiglium, wherein the composition contains at least a component concentration of a reference standard of croton tiglium latex, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of croton tiglium Müll.Arg. croton tiglium Müll.
[0139] water;
[0140] One or more humectants that enhance preservation;
[0141] One or more chelating agents;
[0142] One or more dispersants / co-emulsifiers;
[0143] One or more preservatives;
[0144] One or more emollients;
[0145] One or more anti-flocculating agents;
[0146] One or more thickeners / stabilizers / emulsifiers / conditioners; and
[0147] One or more pH adjusters may be selected.
[0148] The embodiments described herein relate to a hydrogel formulation comprising a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium ethylenediaminetetraacetate dihydrate, methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglyceride, and SEPINEO. TM P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80).
[0149] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably the component concentration of a filtered latex of croton tiglium, preferably the component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium ethylenediaminetetraacetate dihydrate, and... 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbyl palmitate, D,L-α-tocopherol), methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglycerides, SEPINEO TM P 600 (acrylamide / acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80), sodium benzoate, potassium sorbate, and triethanolamine.
[0150] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably the component concentration of a filtered latex of croton tiglium, preferably the component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium ethylenediaminetetraacetate dihydrate, and... 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbyl palmitate, D,L-α-tocopherol), methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglycerides, SEPINEO TM P 600 (acrylamide / acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80), sodium benzoate and potassium sorbate.
[0151] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium EDTA dihydrate, methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglyceride, and SEPINEO. TM P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80), wherein the Peruvian croton contains at least about 110 PPM of gallocatechin, at least about 780 PPM of epigallocatechin, at least about 1.6 PPM of catechin, at least about 2 PPM of epicatechin, at least about 45 PPM of taspine, at least about 0.1 PPM of dimethylcedrusin, and wherein the Peruvian croton has a polydispersity index of about 0.5 to about 0.85.
[0152] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably the component concentration of a filtered latex of croton tiglium, preferably the component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium ethylenediaminetetraacetate dihydrate, and... 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbyl palmitate, D,L-α-tocopherol), methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglycerides, SEPINEO TM P 600 (acrylamide / acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80), sodium benzoate, potassium sorbate, triethanolamine, wherein the Peruvian croton contains at least about 110 PPM of gallocatechin, at least about 780 PPM of epigallocatechin, at least about 1.6 PPM of catechin, at least about 2 PPM of epicatechin, at least about 45 PPM of taspine, at least about 0.1 PPM of dimethyl cedryatin, and wherein the Peruvian croton has a polydispersity index of about 0.5 to about 0.85.
[0153] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably the component concentration of a filtered latex of croton tiglium, preferably the component concentration of a filtered latex of Müll. Arg. croton tiglium), propylene glycol, disodium ethylenediaminetetraacetate dihydrate, and... 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbyl palmitate, D,L-α-tocopherol), methylparaben, propylparaben, water, dimethyl silicone oil, caprylic / capric triglycerides, SEPINEO TM P 600 (acrylamide / acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80), sodium benzoate, potassium sorbate, wherein the Peruvian croton contains at least about 110 PPM of gallocatechin, at least about 780 PPM of epigallocatechin, at least about 1.6 PPM of catechin, at least about 2 PPM of epicatechin, at least about 45 PPM of taspine, at least about 0.1 PPM of dimethyl cedryatin, and wherein the Peruvian croton has a polydispersity index of about 0.5 to about 0.85.
[0154] The embodiments described herein relate to a hydrogel formulation comprising: a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of a reference standard of croton tiglium latex, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of Müll. Arg. croton tiglium), glycerol, methylparaben, propylparaben, water, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate, sodium hexametaphosphate, medium-chain triglycerides, and SEPINEO. TM P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80), wherein the Peruvian croton contains at least about 110 PPM of gallocatechin, at least about 780 PPM of epigallocatechin, at least about 1.6 PPM of catechin, at least about 2 PPM of epicatechin, at least about 45 PPM of taspine, at least about 0.1 PPM of dimethyl cedryatin, and wherein the Peruvian croton has a polydispersity index of about 0.5 to about 0.85.
[0155] In some embodiments of the hydrogel formulation, the filtered latex of Peruvian croton is Müll.Arg. filtered latex of Peruvian croton.
[0156] In some embodiments, the latex of croton burmannii, preferably the filtered latex of croton burmannii, and preferably the filtered latex of Müll.Arg. croton burmannii, contains one or more compounds selected from gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin, and combinations thereof.
[0157] Each of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin may be present in the latex of said croton, preferably the filtered latex of croton, and preferably the filtered latex of Müll.Arg. croton, at least in the amount found in Table 1a or in any combination of these amounts.
[0158] The embodiments described herein relate to hydrogel formulations comprising a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, and a pharmaceutically acceptable excipient. In some embodiments, the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium comprises one or more compounds selected from gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin, and combinations thereof. Each of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin may be present in the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, at least in amounts found in Table 1a or in any combination of these amounts.
[0159] As shown in Table B, a wide range of compounds are present in AB-101. The main bioactive reference standards for pharmaceutical-grade AB-101 are gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin. Particularly important are the second group of polyphenolic bioactive substances comprised of the gallate family, including catechin gallate (CG), epicatechin gallate (ECG), gallocatechin gallate (GCG), and epigallocatechin gallate (EGCG). The bioactive properties of the gallate family, particularly important to AB-101, include antimicrobial and antioxidant properties. These properties have been mentioned and specified in the following literature: Rahardiyan, Dino, (2018), Antibacterial potential of catechin of tea (Camelliasinensis) and its applications, Food Research, 3.1-6, and Multifunctional Antioxidant Activities of Alkyl Gallates, The OpenBioactive Compounds Journal, 2010, 3:1-11. Isao Kubo, Noriyoshi Masuoka, Tae Joung Ha, Kuniyoshi Shimizu, Ken-ichi Nihei.
[0160] From a compositional perspective, major and minor bioactive substances comprise 80% to 99% of the concentration of pharmaceutical-grade AB-101, with the remaining uncharacterized compounds constituting the remainder of AB-101. Overall, the gallate bioactive substance family contributes between 1% and 20% of the bioactivity. For AB-101 lot 01, the major bioactive reference ranges from 85% to 90%, the minor reference ranges from 3% to 4%, and the total uncharacterized compounds in AB-101 range from 7% to 11%.
[0161] The latex of whole Müll. Arg. Peruvian croton contributes a unique synergistic effect throughout the composition, meeting specific bioassay performance targets and producing a composition with good natural polydispersity as measured by polydispersity index analysis. The primary reference standard is the main focus of the bioactivity of pharmaceutical grade AB-101, while the secondary reference standards demonstrate the biodiversity, polydispersity, and synergistic composition within AB-101, which also contributes to the therapeutic efficacy of AB-101.
[0162] Table 1a
[0163]
[0164]
[0165] Table 1b
[0166]
[0167] Table 1c – Exemplary Antibiotic Activities
[0168] bacteria Exemplary MIC Example MBC Methicillin-susceptible Staphylococcus aureus (MSSA) 50 μg / mL or lower 50 μg / mL or lower Methicillin-resistant Staphylococcus aureus (MRSA) 50 μg / mL or lower 50 μg / mL or lower Pseudomonas aeruginosa 50 μg / mL or lower 50 μg / mL or lower Streptococcus pyogenes 50 μg / mL or lower 50 μg / mL or lower
[0169] Table 1d - Gallic catechin, Epigallocatechin, Catechin, Epicatechin and Taspin
[0170] Example LogP of each of the bases
[0171] IVPT: Calculation of skin permeability flux for ECG <![CDATA[at least about less than 500 μg / cm 2 / hr]]> IVRT: Calculation of API (Active Pharmaceutical Ingredient) Release Flux from ECG <![CDATA[at least about less than 2400 μg / cm 2 / hr]]> ECG LogP: Calculation of distribution coefficients At least approximately or less than 2.5
[0172] Table 1e - Exemplary Other Properties
[0173] Film-forming properties Observed on the skin
[0174] If the latex of the Peruvian croton, preferably the filtered latex of the Peruvian croton, preferably the filtered latex of the Müll.Arg. Peruvian croton, does not contain at least the amounts of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin described herein, then it is not suitable for use in the hydrogel formulations and methods of use described herein.
[0175] In some embodiments, the amount of gallic catechin present in the latex is at least about 110 PPM, at least about 115 PPM, at least about 120 PPM, at least about 125 PPM, at least about 130 PPM, at least about 135 PPM, at least about 140 PPM, at least about 145 PPM, at least about 150 PPM, at least about 155 PPM, at least about 160 PPM, at least about 165 PPM, at least about 170 PPM, at least about 175 PPM, at least about 180 PPM, at least about 185 PPM, at least about 190 PPM, at least about 195 PPM, at least about 200 PPM, or a range between any two of these values.
[0176] In some embodiments, the amount of epigallocatechin present in the latex is at least about 780 PPM, at least about 790 PPM, at least about 800 PPM, at least about 810 PPM, at least about 820 PPM, at least about 830 PPM, at least about 840 PPM, at least about 850 PPM, at least about 860 PPM, at least about 870 PPM, at least about 880 PPM, at least about 890 PPM, at least about 900 PPM, at least about 910 PPM, at least about 920 PPM, at least about 930 PPM, at least about 940 PPM, at least about 950 PPM, at least about 960 PPM, at least about 970 PPM, at least about 980 PPM, at least about 990 PPM, and so on. At least 1000 PPM, at least 1010 PPM, at least 1020 PPM, at least 1030 PPM, at least 1040 PPM, at least 1050 PPM, at least 1060 PPM, at least 1070 PPM, at least 1080 PPM, at least 1090 PPM, at least 1100 PPM, at least 1110 PPM, at least 1120 PPM, at least 1130 PPM, at least 1140 PPM, at least 1150 PPM, at least 1160 PPM, at least 1170 PPM, at least 1180 PPM, at least 1190 PPM, at least 1200 PPM, at least 1210 PPM, at least 1220 PPM PM, at least approximately 1230 PPM, at least approximately 1240 PPM, at least approximately 1250 PPM, at least approximately 1260 PPM, at least approximately 1270 PPM, at least approximately 1280 PPM, at least approximately 1290 PPM, at least approximately 1300 PPM, at least approximately 1310 PPM, at least approximately 1320 PPM, at least approximately 1330 PPM, at least approximately 1340 PPM, at least approximately 1350 PPM, at least approximately 1360 PPM, at least approximately 1370 PPM, at least approximately 1380 PPM, at least approximately 1390 PPM, at least approximately 1400 PPM, at least approximately 1410 PPM, at least approximately 1420 PPM, at least approximately 1430 PPM, at least approximately 1440 PPM, at least approximately 1 450 PPM, at least approximately 1460 PPM, at least approximately 1470 PPM, at least approximately 1480 PPM, at least approximately 1490 PPM, at least approximately 1500 PPM, at least approximately 1510 PPM, at least approximately 1520 PPM, at least approximately 1530 PPM, at least approximately 1540 PPM, at least approximately 1550 PPM, at least approximately 1560 PPM, at least approximately 1570 PPM, at least approximately 1580 PPM, at least approximately 1590 PPM, at least approximately 1600 PPM, at least approximately 1610 PPM, at least approximately 1620 PPM, at least approximately 1630 PPM, at least approximately 1640 PPM, at least approximately 1650 PPM, at least approximately 1660 PPM, at least approximately 1670 PPM.At least approximately 1680 PPM, at least approximately 1690 PPM, at least approximately 1700 PPM, or a range between any two of these values.
[0177] In some embodiments, the amount of catechins present in the latex is at least about 1.6 PPM, at least about 1.7 PPM, at least about 1.8 PPM, at least about 1.9 PPM, at least about 2.0 PPM, at least about 2.1 PPM, at least about 2.2 PPM, at least about 2.3 PPM, at least about 2.4 PPM, at least about 2.5 PPM, at least about 2.6 PPM, at least about 2.7 PPM, at least about 2.8 PPM, at least about 2.9 PPM, at least about 3.0 PPM, at least about 3.1 PPM, at least about 3.2 PPM, at least about 3.3 PPM, at least about 3.4 PPM, at least about 3.5 PPM, at least about 3.6 PPM, at least about 3.7 PPM, and at least about 3.8 PPM. PPM, at least approximately 3.9 PPM, at least approximately 4.0 PPM, at least approximately 4.1 PPM, at least approximately 4.2 PPM, at least approximately 4.3 PPM, at least approximately 4.4 PPM, at least approximately 4.5 PPM, at least approximately 4.6 PPM, at least approximately 4.7 PPM, at least approximately 4.8 PPM, at least approximately 4.9 PPM, at least approximately 5.0 PPM, at least approximately 5.1 PPM, at least approximately 5.2 PPM, at least approximately 5.3 PPM, at least approximately 5.4 PPM, at least approximately 5.5 PPM, at least approximately 5.6 PPM, at least approximately 5.7 PPM, at least approximately 5.8 PPM, at least approximately 5.9 PPM, at least approximately 6.0 PPM, at least approximately 6.1 PPM, at least approximately 6.2 PPM, at least approximately 6.3 PPM PPM, at least approximately 6.4 PPM, at least approximately 6.5 PPM, at least approximately 6.6 PPM, at least approximately 6.7 PPM, at least approximately 6.8 PPM, at least approximately 6.9 PPM, at least approximately 7.0 PPM, at least approximately 7.1 PPM, at least approximately 7.2 PPM, at least approximately 7.3 PPM, at least approximately 7.4 PPM, at least approximately 7.5 PPM, at least approximately 7.6 PPM, at least approximately 7.7 PPM, at least approximately 7.8 PPM, at least approximately 7.9 PPM, at least approximately 8.0 PPM, at least approximately 8.1 PPM, at least approximately 8.2 PPM, at least approximately 8.3 PPM, at least approximately 8.4 PPM, at least approximately 8.5 PPM, at least approximately 8.6 PPM, at least approximately 8.7 PPM, at least approximately 8. 8 PPM, at least about 8.9 PPM, at least about 9.0 PPM, at least about 9.1 PPM, at least about 9.2 PPM, at least about 9.3 PPM, at least about 9.4 PPM, at least about 9.5 PPM, at least about 9.6 PPM, at least about 9.7 PPM, at least about 9.8 PPM, at least about 9.9 PPM, at least about 10.0 PPM, at least about 10.1 PPM, at least about 10.2 PPM, at least about 10.3 PPM, at least about 10.4 PPM, at least about 10.5 PPM, at least about 10.6 PPM, at least about 10.7 PPM, at least about 10.8 PPM, at least about 10.9 PPM, at least about 11.0 PPM, or a range between any two of these values.
[0178] In some embodiments, the amount of epicatechin present in the latex is at least about 2.0 PPM, at least about 2.1 PPM, at least about 2.2 PPM, at least about 2.3 PPM, at least about 2.4 PPM, at least about 2.5 PPM, at least about 2.6 PPM, at least about 2.7 PPM, at least about 2.8 PPM, at least about 2.9 PPM, at least about 3.0 PPM, at least about 3.1 PPM, at least about 3.2 PPM, at least about 3.3 PPM, at least about 3.4 PPM, at least about 3.5 PPM, at least about 3.6 PPM, at least about 3.7 PPM, and at least about 3.8 PPM. M, at least approximately 3.9 PPM, at least approximately 4.0 PPM, at least approximately 4.1 PPM, at least approximately 4.2 PPM, at least approximately 4.3 PPM, at least approximately 4.4 PPM, at least approximately 4.5 PPM, at least approximately 4.6 PPM, at least approximately 4.7 PPM, at least approximately 4.8 PPM, at least approximately 4.9 PPM, at least approximately 5.0 PPM, at least approximately 5.1 PPM, at least approximately 5.2 PPM, at least approximately 5.3 PPM, at least approximately 5.4 PPM, at least approximately 5.5 PPM, at least approximately 5.6 PPM, at least approximately 5.7 PPM, at least approximately 5.8 PPM, at least approximately 5.9 PPM At least approximately 6.0 PPM, at least approximately 6.1 PPM, at least approximately 6.2 PPM, at least approximately 6.3 PPM, at least approximately 6.4 PPM, at least approximately 6.5 PPM, at least approximately 6.6 PPM, at least approximately 6.7 PPM, at least approximately 6.8 PPM, at least approximately 6.9 PPM, at least approximately 7.0 PPM, at least approximately 7.1 PPM, at least approximately 7.2 PPM, at least approximately 7.3 PPM, at least approximately 7.4 PPM, at least approximately 7.5 PPM, at least approximately 7.6 PPM, at least approximately 7.7 PPM, at least approximately 7.8 PPM, at least approximately 7.9 PPM, at least approximately 8.0 PPM, at least Approximately 8.1 PPM, at least approximately 8.2 PPM, at least approximately 8.3 PPM, at least approximately 8.4 PPM, at least approximately 8.5 PPM, at least approximately 8.6 PPM, at least approximately 8.7 PPM, at least approximately 8.8 PPM, at least approximately 8.9 PPM, at least approximately 9.0 PPM, at least approximately 9.1 PPM, at least approximately 9.2 PPM, at least approximately 9.3 PPM, at least approximately 9.4 PPM, at least approximately 9.5 PPM, at least approximately 9.6 PPM, at least approximately 9.7 PPM, at least approximately 9.8 PPM, at least approximately 9.9 PPM, at least approximately 10.0 PPM, or a range between any two of these values.
[0179] In some embodiments, the amount of taspine present in the latex is at least about 45 PPM, at least about 46 PPM, at least about 47 PPM, at least about 48 PPM, at least about 49 PPM, at least about 50 PPM, at least about 51 PPM, at least about 52 PPM, at least about 53 PPM, at least about 54 PPM, at least about 55 PPM, at least about 56 PPM, at least about 57 PPM, at least about 58 PPM, at least about 59 PPM, at least about 60 PPM, at least about 61 PPM, at least about 62 PPM, at least about 63 PPM, at least about 64 PPM, at least about 65 PPM, or a range between any two of these values.
[0180] In some embodiments, the amount of dimethyl cedryatin present in the latex is at least about 0.1 mg dimethyl cedryatin / kg latex, at least about 0.11 PPM, at least about 0.12 PPM, at least about 0.13 PPM, at least about 0.14 PPM, at least about 0.15 PPM, at least about 0.16 PPM, at least about 0.17 PPM, at least about 0.18 PPM, at least about 0.18 PPM, at least about 0.19 PPM, at least about 0.20 PPM, at least about 0.21 PPM, at least about 0.22 PPM, at least about 0.23 PPM, at least about 0.24 PPM, at least about 0.25 PPM, at least about 0.26 PPM, at least about 0.27 PPM, and at least about 0. 28 PPM, at least approximately 0.29 PPM, at least approximately 0.30 PPM, at least approximately 0.31 PPM, at least approximately 0.32 PPM, at least approximately 0.33 PPM, at least approximately 0.34 PPM, at least approximately 0.35 PPM, at least approximately 0.36 PPM, at least approximately 0.37 PPM, at least approximately 0.38 PPM, at least approximately 0.39 PPM, approximately 0.40 PPM, at least approximately 0.41 PPM, at least approximately 0.42 PPM, at least approximately 0.43 PPM, at least approximately 0.44 PPM, at least approximately 0.45 PPM, at least approximately 0.46 PPM, at least approximately 0.47 PPM, at least approximately 0.48 PPM, at least approximately 0.49 PPM, at least approximately 0.5 PPM, at least approximately 0. 6 PPM, at least approximately 0.7 PPM, at least approximately 0.8 PPM, at least approximately 0.9 PPM, at least approximately 1.0 PPM, at least approximately 1.1 PPM, at least approximately 1.2 PPM, at least approximately 1.3 PPM, at least approximately 1.4 PPM, at least approximately 1.5 PPM, at least approximately 1.6 PPM, at least approximately 1.7 PPM, at least approximately 1.8 PPM, at least approximately 1.9 PPM, at least approximately 2.0 PPM, at least approximately 2.1 PPM, at least approximately 2.2 PPM, at least approximately 2.3 PPM, at least approximately 2.4 PPM, at least approximately 2.5 PPM, at least approximately 2.6 PPM, at least approximately 2.7 PPM, at least approximately 2.8 PPM, at least approximately 2.9 PPM, at least approximately 3.0 PPM, at least approximately 3. 1 PPM, at least approximately 3.2 PPM, at least approximately 3.3 PPM, at least approximately 3.4 PPM, at least approximately 3.5 PPM, at least approximately 3.6 PPM, at least approximately 3.7 PPM, at least approximately 3.8 PPM, at least approximately 3.9 PPM, at least approximately 4.0 PPM, at least approximately 4.1 PPM, at least approximately 4.2 PPM, at least approximately 4.3 PPM, at least approximately 4.4 PPM, at least approximately 4.5 PPM, at least approximately 4.6 PPM, at least approximately 4.7 PPM, at least approximately 4.8 PPM, at least approximately 4.9 PPM, at least approximately 5.0 PPM, at least approximately 5.1 PPM, at least approximately 5.2 PPM, at least approximately 5.3 PPM, at least approximately 5.4 PPM, at least approximately 5.5 PPM, at least approximately 5.6 PPM, at least approximately 5.7 PPM, at least approximately 5.8 PPM, at least approximately 5.9 PPM, at least approximately 6.0 PPM, at least approximately 6.1 PPM, at least approximately 6.2 PPM, at least approximately 6.3 PPM, at least approximately 6.4 PPM, at least approximately 6.5 PPM, at least approximately 6.6 PPM, at least approximately 6.7 PPM, at least approximately 6.8 PPM, at least approximately 6.9 PPM, at least approximately 7.0 PPM, at least approximately 7.1 PPM, at least approximately 7.2 PPM, at least approximately 7.3 PPM, at least approximately 7.4 PPM, at least approximately 7.5 PPM, at least approximately 7.6 PPM, at least approximately 7.7 PPM, at least approximately 7.8 PPM, at least approximately 7. 9 PPM, at least approximately 8.0 PPM, at least approximately 8.1 PPM, at least approximately 8.2 PPM, at least approximately 8.3 PPM, at least approximately 8.4 PPM, at least approximately 8.5 PPM, at least approximately 8.6 PPM, at least approximately 8.7 PPM, at least approximately 8.8 PPM, at least approximately 8.9 PPM, at least approximately 9.0 PPM, at least approximately 9.1 PPM, at least approximately 9.2 PPM, at least approximately 9.3 PPM, at least approximately 9.4 PPM, at least approximately 9.5 PPM, at least approximately 9.6 PPM, at least approximately 9.7 PPM, at least approximately 9.8 PPM, at least approximately 9.9 PPM, at least approximately 10.0 PPM, or a range between any two of these values.
[0181] In some embodiments, the hydrogel formulation is suitable for topical application (including, for example, the dermis, oral mucosa, buccal mucosa, sublingual mucosa, intraocular region, and wound cavity).
[0182] In certain embodiments of the hydrogel formulation, the amount of the croton latex, preferably the filtered croton latex, and preferably the filtered croton latex of Müll. Arg. croton (wherein the composition contains at least the component concentration of the croton latex of the reference standard, the component concentration of the filtered croton latex of croton, and the component concentration of the filtered croton latex of Müll. Arg. croton) is about 5% to about 80%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, and about 55% to about 80%. %, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 5% to about 75%, about 5% to about 70%, about 5% to about 65%, about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about 75%, about 15% to about 70%, about 20% to about 65%, about 25% to about 60%, about 30% to about 55%, about 35% to about 55%, about 40% to about 50%, or values within one of these ranges. Specific examples may include about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the latex of croton tiglium, preferably the filtered latex of croton tiglium, and preferably the filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of the reference standard croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of Müll. Arg. croton tiglium) is about 40%. In some embodiments of the hydrogel formulation, the amount of the latex of croton tiglium, preferably the filtered latex of croton tiglium, and preferably the filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of the reference standard croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, and preferably the component concentration of the filtered latex of Müll. Arg. croton tiglium) is about 50%.In some embodiments of the hydrogel formulation, the amount of the latex of croton tiglium, preferably the filtered latex of croton tiglium, preferably the filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of the reference standard croton tiglium latex, preferably the component concentration of the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of croton tiglium) is about 43%. In some embodiments of the hydrogel formulation, the amount of the latex of croton tiglium, preferably the filtered latex of croton tiglium, preferably the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of croton tiglium, preferably the component concentration of the filtered latex of croton tiglium) is about 45%. The above percentages are relative to the composition made from AB-101, wherein AB-101 has exemplary contents of marker compounds present in the latex as disclosed in Table 1a. For example, a pharmaceutical composition containing 100% AB-101 will contain at least about 110 PPM of gallocatechin, while a pharmaceutical composition containing 200% AB-101 will contain at least about 220 PPM of gallocatechin. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0183] In some embodiments of the hydrogel formulation, the one or more preservative-enhancing humectants are selected from... The group consists of USP, propylene glycol and combinations thereof.
[0184] In certain embodiments of the hydrogel formulation, the amount of the one or more preservative-enhancing humectants is about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, about 5% to about 6%, or values within one of these ranges. Specific examples may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more preservative-enhancing humectants is about 5%. In some embodiments of the hydrogel formulation, the amount of the one or more preservative-enhancing humectants is about 4%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0185] In some embodiments of the hydrogel formulation, the one or more chelating agents are selected from the group consisting of disodium ethylenediaminetetraacetate dihydrate, disodium EDTA, and combinations thereof.
[0186] In certain embodiments of the hydrogel formulation, the amount of the one or more chelating agents is about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, about 0.05% to about 0.35%, about 0 The values are approximately 0.05% to 0.3%, approximately 0.05% to 0.25%, approximately 0.05% to 0.2%, approximately 0.05% to 0.15%, approximately 0.05% to 0.1%, approximately 0.1% to 0.45%, approximately 0.15% to 0.4%, approximately 0.2% to 0.35%, approximately 0.25% to 0.30%, approximately 0.05% to 0.25%, approximately 0.075% to 0.225%, approximately 0.1% to 0.2%, approximately 0.125% to 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more chelating agents is about 0.15%. In some embodiments of the hydrogel formulation, the amount of the one or more chelating agents is about 0.10%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0187] In some embodiments of the hydrogel formulation, the one or more dispersants / co-emulsifiers are selected from... The group consists of 50PG, phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol, and combinations thereof.
[0188] In certain embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.5% to about 5%, about 1% to about 3%, 0.5% to about 2%, about 0.05% to about 0.2%, about 0.25% to about 1.25%, about 0.01% to about 0.1%, about 0.001% to about 0.01%, about 0.005% to about 0.02%, or a value within one of these ranges. Specific examples may include about 0.001%, about 0.004%, about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 2%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 1%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.824%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.676%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.12%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.05%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.03%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.01%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.004%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.8%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.7%. In some embodiments of the hydrogel formulation, the amount of the one or more dispersants / co-emulsifiers is about 0.1%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0189] In some embodiments of the hydrogel formulation, the one or more preservatives are selected from the group consisting of methylparaben, propylparaben, sodium benzoate, potassium sorbate, and combinations thereof.
[0190] In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is from about 0.005% to about 0.1%, from about 0.1% to about 1%, from about 0.05% to about 0.5%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.45%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is about 0.45%. In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is about 0.4%. In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is about 0.1%. In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is about 0.02%. In some embodiments of the hydrogel formulation, the amount of the one or more preservatives is about 0.5%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0191] In some embodiments of the hydrogel formulation, the one or more emollients are selected from DOWN. Q7 9120 (Pharmaceutical Grade), Dow 200Fluid350cSt, LABRAFAC TM The group consists of WL1349, dimethyl silicone oil, medium-chain triglycerides and combinations thereof.
[0192] In certain embodiments of the hydrogel formulation, the amount of the one or more emollients is about 0.5% to about 10%, about 1% to about 10%, about 1.5% to about 10%, about 2% to about 10%, about 2.5% to about 10%, about 3% to about 10%, about 3.5% to about 10%, about 4% to about 10%, about 4.5% to about 10%, about 5% to about 10%, about 5.5% to about 10%, about 6% to about 10%, about 6.5% to about 10%, about 7% to about 10%, about 7.5% to about 10%, about 8% to about 10%, about 8.5% to about 10%, about 9% to about 10%, about 9.5% to about 10%, about 0.5% to about 9.5%, about 0.5% to about 9%, about 0.5% to about 8.5%, about 0.5% to about 8%, about 0.5% to about 7.5%, about 0% to about 0% to 10%, ... 0.5% to about 7%, about 0.5% to about 6.5%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1%. Values of about 1% to about 9.5%, about 1.5% to about 9%, about 2% to about 8.5%, about 0.5% to about 8%, about 3% to about 7.5%, about 3.5% to about 7%, about 4% to about 6.5%, about 4.5% to about 6%, about 5% to about 5.5%, about 1% to about 5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or values within one of these ranges. Specific examples may include about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more emollients is about 2%. In some embodiments of the hydrogel formulation, the amount of the one or more emollients is about 2.5%. In some embodiments of the hydrogel formulation, the amount of the one or more emollients is about 5%. In some embodiments of the hydrogel formulation, the amount of the one or more emollients is about 7%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0193] In some embodiments of the hydrogel formulation, the one or more thickeners / stabilizers / emulsifiers are selected from SEPINEO. TMP 600 (acrylamide / acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80), acrylamide / acryloyl dimethyl taurate copolymer, isohexadecane, polysorbate 80 and combinations thereof.
[0194] In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers is about 0.05% to about 10%, about 0.05% to about 5%, about 0.05% to about 1%, about 0.5% to about 3%, 0.5% to about 2%, 0.5% to about 1.5%, about 0.5% to about 1%, about 2% to about 6%, or a value within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers is about 4%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 1.4%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 1.6%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 0.8%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 1%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 0.2%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 0.4%. In some embodiments of the hydrogel formulation, the amount of the one or more thickeners / stabilizers / emulsifiers / conditioners is about 1.3%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0195] In some embodiments of the hydrogel formulation, the one or more pH adjusters are triethanolamine.
[0196] In some embodiments of the hydrogel formulation, the amount of the one or more pH adjusters is about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, about 0.05% to about 0.35%, about 0.05% to about 0.3%, about 0.05% to about 0.25%, about 0.05% to about 0.2%, about 0.05% to about 0.15%, about 0.05% to about 0.1%, about 0.1% to about 0.45%, about 0.15% to about 0.4%, about 0.2% to about 0.35%, about 0.25% to about 0.30%, about 0.05% to about 0.25%, about 0.075% to about 0.225%, about 0.1% to about 0.2%, about 0.125% to about 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, about 0.325%, about 0.35%, about 0.375%, about 0.4%, about 0.425%, about 0.45%, about 0.475%, about 0.5%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of the one or more pH adjusters is about 0.26%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0197] In certain embodiments of the hydrogel formulation, the amount of propylene glycol is about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, about 5% to about 6%, or a value within one of these ranges. Specific examples may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of propylene glycol is about 5%. In some embodiments of the hydrogel formulation, the amount of propylene glycol is about 4%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0198] In certain embodiments of the hydrogel formulation, the amount of the disodium ethylenediaminetetraacetate dihydrate is about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, about 0.05% to about 0.35%, etc. The values are approximately 0.05% to approximately 0.3%, approximately 0.05% to approximately 0.25%, approximately 0.05% to approximately 0.2%, approximately 0.05% to approximately 0.15%, approximately 0.05% to approximately 0.1%, approximately 0.1% to approximately 0.45%, approximately 0.15% to approximately 0.4%, approximately 0.2% to approximately 0.35%, approximately 0.25% to approximately 0.30%, approximately 0.05% to approximately 0.25%, approximately 0.075% to approximately 0.225%, approximately 0.1% to approximately 0.2%, approximately 0.125% to approximately 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of the disodium ethylenediaminetetraacetate dihydrate is about 0.15%. In some embodiments of the hydrogel formulation, the amount of the disodium ethylenediaminetetraacetate dihydrate is about 0.10%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0199] In some embodiments of the hydrogel formulation, the The amount of 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) is about 0.5% to about 5%, about 1% to about 3%, 0.5% to about 2%, about 0.05% to about 0.2%, about 0.25% to about 1.25%, about 0.01% to about 0.1%, about 0.001% to about 0.01%, about 0.005% to about 0.02%, or a value within one of these ranges. Specific examples may include about 0.001%, about 0.004%, about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the... The amount of 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) is about 2%. All of the above represent weight percentages of the embodiments of the hydrogel formulation.
[0200] In some embodiments of the hydrogel formulation, the amount of methylparaben is about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, about 0.05% to about 0.35%, about 0 The values are approximately 0.05% to 0.3%, approximately 0.05% to 0.25%, approximately 0.05% to 0.2%, approximately 0.05% to 0.15%, approximately 0.05% to 0.1%, approximately 0.1% to 0.45%, approximately 0.15% to 0.4%, approximately 0.2% to 0.35%, approximately 0.25% to 0.30%, approximately 0.05% to 0.25%, approximately 0.075% to 0.225%, approximately 0.1% to 0.2%, approximately 0.125% to 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of methylparaben is about 0.15%. In some embodiments of the hydrogel formulation, the amount of methylparaben is about 0.1%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0201] In certain embodiments of the hydrogel formulation, the amount of propylparaben is about 0.005% to about 0.05%, about 0.01% to about 0.05%, about 0.015% to about 0.05%, about 0.02% to about 0.05%, about 0.025% to about 0.05%, about 0.03% to about 0.05%, about 0.035% to about 0.05%, about 0.04% to about 0.05%, about 0.045% to about 0.05%, about 0.005% to about 0.045%, about 0.005% to... The values are approximately 0.04%, approximately 0.005% to approximately 0.035%, approximately 0.005% to approximately 0.03%, approximately 0.005% to approximately 0.025%, approximately 0.005% to approximately 0.02%, approximately 0.005% to approximately 0.015%, approximately 0.005% to approximately 0.01%, approximately 0.01% to approximately 0.045%, approximately 0.02% to approximately 0.04%, approximately 0.025% to approximately 0.035%, approximately 0.02% to approximately 0.04%, approximately 0.015% to approximately 0.045%, or values within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.015%, about 0.02%, about 0.025%, about 0.03%, about 0.035%, about 0.04%, about 0.045%, about 0.05%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of propylparaben is about 0.02%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0202] In some embodiments of the hydrogel formulation, the amount of sodium benzoate is from about 0.005% to about 0.1%, from about 0.1% to about 1%, from about 0.05% to about 0.5%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.45%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of sodium benzoate is about 0.40%. In some embodiments of the hydrogel formulation, the amount of sodium benzoate is about 0.45%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0203] In some embodiments of the hydrogel formulation, the amount of potassium sorbate is from about 0.005% to about 0.1%, from about 0.1% to about 1%, from about 0.05% to about 0.5%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.45%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of potassium sorbate is about 0.45%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0204] In some embodiments of the hydrogel formulation, the amount of water is about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 20% to about 75%, or about 20%. The percentage may be approximately 70%, approximately 20% to approximately 65%, approximately 20% to approximately 60%, approximately 20% to approximately 55%, approximately 20% to approximately 50%, approximately 20% to approximately 45%, approximately 20% to approximately 40%, approximately 20% to approximately 35%, approximately 20% to approximately 30%, approximately 20% to approximately 25%, approximately 25% to approximately 75%, approximately 30% to approximately 70%, approximately 35% to approximately 65%, approximately 40% to approximately 60%, approximately 45% to approximately 55%, or values within one of these ranges. Specific examples may include approximately 20%, approximately 25%, approximately 30%, approximately 35%, approximately 40%, approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately 65%, approximately 60%, approximately 75%, approximately 80%, or any two of these values. In some embodiments of the hydrogel formulation, the amount of water is approximately 43.38%. In some embodiments of the hydrogel formulation, the amount of water is about 33.38%. In some embodiments of the hydrogel formulation, the amount of water is about 40.38%. In some embodiments of the hydrogel formulation, the amount of water is about 38.38%. In some embodiments of the hydrogel formulation, the amount of water is about 40.7%. In some embodiments of the hydrogel formulation, the amount of water is about 39%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0205] In certain embodiments of the hydrogel formulation, the amount of dimethyl silicone oil is approximately 0.5% to 10%, approximately 1% to 10%, approximately 1.5% to 10%, approximately 2% to 10%, approximately 2.5% to 10%, approximately 3% to 10%, approximately 3.5% to 10%, approximately 4% to 10%, approximately 4.5% to 10%, approximately 5% to 10%, approximately 5.5% to 10%, approximately 6% to 10%, approximately 6.5% to 10%, approximately 7% to 10%, approximately 7.5% to 10%, approximately 8% to 10%, approximately 8.5% to 10%, approximately 9% to 10%, approximately 9.5% to 10%, approximately 0.5% to 9.5%, approximately 0.5% to 9%, approximately 0.5% to 8.5%, approximately 0.5% to 8%, approximately 0.5% to 7.5%, approximately 0.5%. % to about 7%, about 0.5% to about 6.5%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1%, about Values ranging from 1% to 9.5%, from 1.5% to 9%, from 2% to 8.5%, from 0.5% to 8%, from 3% to 7.5%, from 3.5% to 7%, from 4% to 6.5%, from 4.5% to 6%, from 5% to 5.5%, from 1% to 5%, from 1.5% to 4.5%, from 2% to 4%, from 2.5% to 3.5%, or within one of these ranges. Specific examples may include values from about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, or between any two of these values. In some embodiments of the hydrogel formulation, the amount of dimethyl silicone oil is about 2%. In some embodiments of the hydrogel formulation, the amount of dimethyl silicone oil is about 2.5%. In some embodiments of the hydrogel formulation, the amount of dimethyl silicone oil is about 3%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0206] In certain embodiments of the hydrogel formulation, the dimethyl silicone oil has a concentration of approximately 175 cSt to approximately 525 cSt, approximately 200 cSt to approximately 525 cSt, approximately 225 cSt to approximately 525 cSt, approximately 250 cSt to approximately 525 cSt, approximately 275 cSt to approximately 525 cSt, approximately 300 cSt to approximately 525 cSt, approximately 325 cSt to approximately 525 cSt, approximately 350 cSt to approximately 525 cSt, approximately 375 cSt to approximately 525 cSt, approximately 400 cSt to approximately 525 cSt, approximately 425 cSt to approximately 525 cSt, approximately 450 cSt to approximately 525 cSt, approximately 475 cSt to approximately 525 cSt, approximately 500 cSt to approximately 525 cSt, approximately 175 cSt to approximately 500 cSt, approximately 175 cSt to approximately 475 cSt, and approximately... Viscosities of 175 cSt to about 450 cSt, about 175 cSt to about 425 cSt, about 175 cSt to about 400 cSt, about 175 cSt to about 375 cSt, about 175 cSt to about 350 cSt, about 175 cSt to about 325 cSt, about 175 cSt to about 300 cSt, about 175 cSt to about 275 cSt, about 175 cSt to about 250 cSt, about 175 cSt to about 225 cSt, about 175 cSt to about 200 cSt, about 200 cSt to about 500 cSt, about 225 cSt to about 475 cSt, about 250 cSt to about 450 cSt, about 275 cSt to about 425 cSt, about 300 cSt to about 400 cSt, about 325 cSt to about 375 cSt, or values within one of these ranges. Specific examples may include about 175 cSt, about 200 cSt, about 225 cSt, about 250 cSt, about 275 cSt, about 300 cSt, about 325 cSt, about 350 cSt, about 375 cSt, about 400 cSt, about 425 cSt, about 450 cSt, about 475 cSt, about 500 cSt, about 525 cSt, or a range between any two of these values. In some embodiments of the hydrogel formulation, the dimethyl silicone oil has a viscosity of about 350 cSt.
[0207] In certain embodiments of the hydrogel formulation, the amount of caprylic / capric triglyceride is about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, about 5% to about 6%, or a value within one of these ranges. Specific examples may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of caprylic / capric triglyceride is about 5%. In some embodiments of the hydrogel formulation, the amount of caprylic / capric triglyceride is about 7%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0208] In some embodiments of the hydrogel formulation, the SEPINEO TMThe amount of P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 0.5% to about 10%, about 1% to about 10%, about 1.5% to about 10%, about 2% to about 10%, about 2.5% to about 10%, about 3% to about 10%, about 3.5% to about 10%, about 4% to about 10%, about 4.5% to about 10%, about 5% to about 10%, and about 5%. 5% to about 10%, about 6% to about 10%, about 6.5% to about 10%, about 7% to about 10%, about 7.5% to about 10%, about 8% to about 10%, about 8.5% to about 10%, about 9% to about 10%, about 9.5% to about 10%, about 0.5% to about 9.5%, about 0.5% to about 9%, about 0.5% to about 8.5%, about 0.5% to about 8%, about 0.5% to about 7.5%. %, about 0.5% to about 7%, about 0.5% to about 6.5%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1% %, about 1% to about 9.5%, about 1.5% to about 9%, about 2% to about 8.5%, about 0.5% to about 8%, about 3% to about 7.5%, about 3.5% to about 7%, about 4% to about 6.5%, about 4.5% to about 6%, about 5% to about 5.5%, about 1% to about 5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or values within one of these ranges. Specific examples may include about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the SEPINEO TM The amount of P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 3.3%. In some embodiments of the hydrogel formulation, the SEPINEO... TM The amount of P 600 (acrylamide / acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 4.0%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0209] In certain embodiments of the hydrogel formulation, the amount of triethanolamine is about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, about 0.05% to about 0.35%, or about 0.0%. The values are 5% to about 0.3%, about 0.05% to about 0.25%, about 0.05% to about 0.2%, about 0.05% to about 0.15%, about 0.05% to about 0.1%, about 0.1% to about 0.45%, about 0.15% to about 0.4%, about 0.2% to about 0.35%, about 0.25% to about 0.30%, about 0.05% to about 0.25%, about 0.075% to about 0.225%, about 0.1% to about 0.2%, about 0.125% to about 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, about 0.325%, about 0.35%, about 0.375%, about 0.4%, about 0.425%, about 0.45%, about 0.475%, about 0.5%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of triethanolamine is about 0.26%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0210] In certain embodiments of the hydrogel formulation, the hydrogel formulation has a density of about 3.0 to about 7.0, about 3.5 to about 7.0, about 4.0 to about 7.0, about 4.5 to about 7.0, about 5.0 to about 7.0, about 5.5 to about 7.0, about 6.0 to about 7.0, about 6.5 to about 7.0, about 3.0 to about 6.5, about 3.0 to about 6.0, about 3.0 to about 5.5, about 3.0 to about 5, about 3.0 to about 4.5, about 3.0 to about 4, about 3.0 to about 3.5, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, etc. A pH of about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, or a range between any two of these values. In some embodiments of the hydrogel formulation, the hydrogel formulation has a pH of about 4.0 to about 6.7. In some embodiments of the hydrogel formulation, the hydrogel formulation has a pH of about 3.0 to about 4.0. In some embodiments of the hydrogel formulation, the hydrogel formulation has a pH of about 5.5 to about 6.5.
[0211] In some embodiments, the hydrogel formulation does not contain more than about 2 wt% of monohydroxy alcohol.
[0212] In some embodiments, the hydrogel formulation does not contain sodium cromoglycate.
[0213] In some embodiments of the hydrogel formulation, the amount of glycerol is about 1% to about 5%, about 1.5% to about 5%, about 2% to about 5%, about 2.5% to about 5%, about 3% to about 5%, about 3.5% to about 5%, about 4% to about 5%, about 4.5% to about 5%, about 1% to about 4.5%, about 1% to about 4%, about 1% to about 3.5%, about 1% to about 3%, about 1% to about 2.5%, about 1% to about 2%, about 1% to about 1.5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or a value within one of these ranges. Specific examples may include about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of glycerol is about 3%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0214] In some embodiments of the hydrogel formulation, the amount of disodium hydrogen phosphate heptahydrate is about 1% to about 3%, about 1.5% to about 3%, about 2% to about 3%, about 2.5% to about 3%, about 1% to about 2.5%, about 1% to about 2%, about 1% to about 1.5%, about 1.5% to about 2.5%, or a value within one of these ranges. Specific examples may include about 1%, about 1.5%, about 2%, about 2.5%, about 3%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of disodium hydrogen phosphate heptahydrate is about 2%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0215] In certain embodiments of the hydrogel formulation, the amount of sodium dihydrogen phosphate is about 0.1% to about 0.4%, about 0.15% to about 0.4%, about 0.2% to about 0.4%, about 0.25% to about 0.4%, about 0.3% to about 0.4%, about 0.35% to about 0.4%, about 0.1% to about 0.35%, about 0.1% to about 0.3%, about 0.1% to about 0.25%, about 0.1% to about 0.2%, about 0.1% to about 0.15%, about 0.15% to about 0.35%, about 0.2% to about 0.3%, or a value within one of these ranges. Specific examples may include about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of sodium dihydrogen phosphate is about 0.26%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0216] In some embodiments of the hydrogel formulation, the amount of sodium hexametaphosphate is about 0.005% to about 0.02%, about 0.01% to about 0.02%, about 0.015% to about 0.02%, about 0.005% to about 0.015%, about 0.005% to about 0.01%, about 0.01% to about 0.015%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.015%, about 0.02%, or a range between any two of these values. In some embodiments of the hydrogel formulation, the amount of sodium hexametaphosphate is about 0.01%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0217] In some embodiments of the hydrogel formulation, the amount of the medium-chain triglyceride is about 1% to about 6%, about 1.5% to about 6%, about 2% to about 6%, about 2.5% to about 6%, about 3% to about 6%, about 3.5% to about 6%, about 4% to about 6%, about 4.5% to about 6%, about 5% to about 6%, about 5.5% to about 6%, about 1% to about 5.5%, about 1% to about 5%, about 1% to about 4.5%, about 1% to about 4%, about 1% to about 3.5%, about 1% to about 3%, about 1% to about 2.5%, about 1% to about 2%, about 1% to about 1.5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or a value within one of these ranges. Specific examples may include about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, or a range of any two of these values. In some embodiments of the hydrogel formulation, the amount of the medium-chain triglyceride is about 4%. All of the above represent weight percentages of embodiments of the hydrogel formulation.
[0218] The polydispersity index (PDI) is used to measure the width of the molecular weight distribution of AB-101. PDI indicates the distribution of polymer chain molecular weights in a given polymer; as the PDI value increases, the inhomogeneity in terms of crosslinking, network formation, chain length, branching, and hyperbranching increases, resulting in a more random arrangement. PDI is an important indicator for characterizing the unique compositional properties of AB-101 or other compositions derived from Peruvian croton. In any of the embodiments disclosed herein, the PDI of the latex of Peruvian croton, preferably a filtered latex of Peruvian croton, preferably a filtered latex of Müll.Arg. Peruvian croton, is about 0.5 to about 0.85, about 0.55 to about 0.85, about 0.6 to about 0.85, about 0.65 to about 0.85, about 0.7 to about 0.85, about 0.75 to about 0.85, about 0.8 to about 0.85, about 0.5 to about 0.8, about 0.5 to about 0.75, about 0.5 to about 0.7, about 0.5 to about 0.65, about 0.5 to about 0.6, about 0.5 to about 0.55, or a value within one of these ranges. Specific examples may include about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, or a range between any two of these values. In some embodiments, the latex of the Peruvian croton, preferably the filtered latex of the Peruvian croton, and preferably the filtered latex of the Müll.Arg. Peruvian croton, has a PDI of about 0.81.
[0219] In some embodiments, the hydrogel formulation is as described in Table C:
[0220] Table C
[0221]
[0222]
[0223] In some embodiments, the hydrogel formulation is as described in Table D:
[0224] Table D
[0225]
[0226]
[0227] In some embodiments, the hydrogel formulation is as described in Table E:
[0228] Table E
[0229]
[0230]
[0231] In some embodiments, the hydrogel formulation is as described in Table F:
[0232] Table F
[0233]
[0234] The hydrogel formulation of AB-101 described and claimed herein is a plant-derived material that meets the criteria for consistent and reproducible batch-to-batch performance and reliably delivers the desired health benefits through topical application in a hydrogel formulation. It can be used to treat skin conditions. A challenge with plant-derived materials is that variations in environmental weather, climate, rainfall, harvest time (by season, time of day, or month), geographic location, longitude, latitude, altitude, soil conditions, harvesting protocols, and many other additional conditions can alter plant characteristics, potentially affecting quality. This can affect the plant's bioactivity, leading to inconsistencies in achieving the desired performance results. This presents a challenge to defining pharmaceutical-grade dragon's blood for providing consistent and reproducible therapeutic benefits. The wide diversity of different species known as dragon's blood further exacerbates this situation. For example, the phytochemical and anti-staphylococcal biofilm evaluation of the resin known as *Dracaena draco* L.Spp.draco showed "no activity against free, live Staphylococcus aureus at the highest test concentration of 1000 mcg / ml." In contrast, AB-101 (a latex of *Croton burmannii* containing appropriate levels of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin, preferably a filtered latex of *Croton burmannii*, preferably a filtered latex of *Croton burmannii* Müll.Arg.) is effective against Staphylococcus aureus, specifically methicillin-sensitive *Staphylococcus aureus* (MSSA) or simply *staph* bacteria, and particularly against methicillin-resistant *Staphylococcus aureus* (MRSA), especially mupirocin-resistant MRSA. The common name for Peruvian croton resin, Dragon's Blood or Sangre de grado, has caused confusion in defining the plant-derived medicine and has shown that not all Peruvian croton plants are the same, nor do they provide similar benefits.
[0235] AB-101, namely filtered or unfiltered latex of Croton tiglium, preferably filtered latex of Croton tiglium, and preferably filtered latex of Müll. Arg. Croton tiglium, offers the advantage of consistently delivering pathogen treatment results across different batches despite all confounding conditions. The challenge of using whole latex lies in identifying the compounds that provide performance based on the many bioactive compounds that make up the latex. Even within the same species grown at similar locations, the chemical composition and bioactivity of whole latex vary, and its ability to combat and kill pathogens unexpectedly differs.
[0236] By establishing a determination method to identify when a batch meets predetermined performance standards, an effective method for identifying whole latex has been obtained. Unique analytical and microbiological assays have been developed to identify which batches of filtered or unfiltered Peruvian croton latex, preferably filtered Peruvian croton latex, and preferably Müll. Arg. Peruvian croton latex, possess a combination of components that consistently provide the desired results.
[0237] AB-101 Plant Raw Material (BRM) is a complex plant product consisting of latex of Croton tiglium, preferably filtered latex of Croton tiglium, and preferably filtered latex of Müll. Arg. Croton tiglium, containing specific amounts of certain marker compounds (catechins, gallocatechins, epicatechins, epigallocatechins, taspine, and dimethyl cedrein) (see Table 1a). Liquid chromatography-tandem mass spectrometry (LC-MS / MS) can be used to characterize the presence and levels of these marker compounds for batch-to-batch consistency and reproducibility of AB-101. The marker compounds in AB-101 BRM include proanthocyanidins (catechins, gallocatechins, epicatechins, and epigallocatechins), the alkaloid taspine, and the lignin dimethyl cedrein.
[0238] The published and accepted systematic classifications of *Croton burmannii* by Müll.Arg. are as follows (van Ee & Berry, 2011; Riina et al., 2009; *The Plant List*, 2012; *The Angiosperm Phylogeny Group*, 2009):
[0239] Phylum: Chain-like plant phylum
[0240] Outline: Horsetail Outline
[0241] Subclass: Magnolia
[0242] Order: Magnolia order
[0243] Family: Euphorbiaceae
[0244] Genus: Croton
[0245] Subgenus: Adenophylli
[0246] Group: Round Wood
[0247] Subgroup: Round Wood
[0248] Species: Müll.Arg. Peruvian Croton
[0249] Biodiversity in herbal medicines plays a crucial role in the characterization of constituent compounds. Compounds used as important markers of batch-to-batch consistency in AB-101 need to 1) demonstrate antimicrobial or scarring properties, 2) be present in AB-101, and 3) be detectable using analytical techniques. Using these criteria, the analytical work focused on three classes of compounds: polyphenols (proanthocyanidins), alkaloids (taspine), and lignins (dimethyl cedryatin). Within the proanthocyanidin category, four specific compounds were focused on: catechins, epicatechins, gallocatechins, and epigallocatechins. Taspine is an important compound in the alkaloid category. Finally, dimethyl cedryatin is an important compound in the lignin category. Each of these compounds satisfies the three required elements detailed above. Below are the chemical structures of six compounds used as important markers of batch-to-batch consistency in AB-101.
[0250] Proanthocyanidins
[0251]
[0252] For characterization studies, the AB-101 extract was freeze-dried, and the freeze-dried powder was subjected to three different extraction methods.
[0253] Method 1 – Ultrasonic Polyphenol Extraction. The lyophilized AB-101 extract was dissolved in methanol. The resulting emulsion was then sonicated for 10 minutes and centrifuged for 5 minutes to remove particulate matter. The supernatant was then analyzed by LC-MS / MS.
[0254] Method 2 – Soxhlet Extraction. The lyophilized AB-101 extract was subjected to Soxhlet extraction with 80% ethanol. The ethanol was removed by rotary evaporator. The resulting material was then resuspended in ethanol and analyzed by LC-MS / MS.
[0255] Method 3 – Polyphenol Extraction. The lyophilized AB-101 extract was incubated overnight in the dark with methanol at room temperature. The supernatant was then filtered using a Whatman filter, dried, and resuspended in methanol. The resulting material was then analyzed by LC-MS / MS.
[0256] Figure 1 Representative total ion chromatograms and additional multiple reaction monitoring spectra were depicted to identify key marker compounds in the AB-101 extract. Figure 6 A representative total ion chromatogram of dimethyl cedrylin was depicted. The compound could be detected using any of the three extraction methods.
[0257] Biodiversity introduces significant variability. To capture this variability, NMR methods utilizing "spectral fingerprinting" are employed for overlapping reference standards. These fingerprints capture most components within AB-101 and can be quantified using nuclear magnetic resonance (NMR). An example is shown using NMR spectra from three different AB-101 batches (batch 00, 01, and 02) and two different deuterated solvents (D₂O and d₄-methanol). Figure 2A and 3A In the diagram, the superposition of the spectra of each solvent is shown. Figure 2B and 3B In the study, it was confirmed that there was no significant variability.
[0258] In another NMR analysis using d4-methanol as the solvent, four different batches of AB-101 (batches 00, 01, 02, and X) were compared. The NMR spectra for each batch are shown in... Figure 4A In the image, the superposition of the spectra of each batch is shown. Figure 4B Although the fingerprints of the four batches appear similar, significant differences exist. This is shown by comparing concentration levels (in ppm) based on quantitative and qualitative NMR “fingerprints” of the marker compounds catechin, epicatechin, gallocatechin, epigallocatechin, taspine, and dimethyl cedryatin by LC-MS / MS. The results are shown in Table 2, indicating that batches 1 and 2 are more similar, while batches X and 0 show the greatest difference.
[0259] Table 2
[0260]
[0261]
[0262] Figure 5 AE plotted a bar graph comparing the AB-101 batch analysis results for each of the five marker compounds.
[0263] Batch 00 is an example of a batch that is not suitable for use in the hydrogel formulations and methods of use described herein. Batch X, 01, and 02 are examples of batches that are suitable for use in the hydrogel formulations and methods of use described herein.
[0264] Zheng-Ping Chen's publication, *Studies on the Anti-Tumour, Anti-Bacterial and Wound-Healing Properties of Dragon's Blood*, Planta Med. 60 (1994), demonstrates that identifying the optimal properties of pharmaceutical-grade AB-101 is not readily apparent. Chen used a bioassay to measure the incorporation rate of H-thymidine into cellular DNA in the presence of the test sample. This bioassay provides a measure of the wound-healing properties of the "sap." Chen used latex from *Croton tiglium* (Müll. Arg.) of Ecuador. The assay showed incorporation rates of 68+ / -12 for the dried sap and 88+ / -5 for the methanol extract. According to Chen, both the dried sap and MeOH were found to have a strong inhibitory effect on wound-healing properties. A person skilled in the art would not assume that the latex extract of *Croton tiglium* (Müll. Arg.) as a whole would be effective in terms of wound-healing properties. Furthermore, Chen pointed out that the Ecuadorian sap contained only trace amounts of taspine. Concerned that taspine is a cytotoxic agent, Chen wanted to minimize or eliminate it entirely. Chen evaluated specific compounds through extraction. Specifically, in this case, gallocatechin and epigallocatechin were assessed as mildly stimulating cell proliferation, while catechin and epicatechin showed almost no effect. Chen further noted that taspine and dimethyl cedryatin had virtually no healing effect in the Ecuadorian sap.
[0265] Pharmaceutical-grade AB-101 has identified a unique composition that maximizes healing performance while maintaining film-forming properties, low LogP, and antibiotic activity. Although Chen does not use whole Müll. Arg. croton latex containing taspinine or dimethyl cedryatin, pharmaceutical-grade AB-101 maintains the use of whole Müll. Arg. croton latex in the composition to obtain the pharmaceutical benefits associated with local wound healing. Taspinine has antibiotic, antiviral, and anti-inflammatory properties. Dimethyl cedryatin has unique fibroblast-stimulating properties that promote healing. The target for taspinine is at least about 45 PPM, and the target for dimethyl cedryatin is a detectable presence of at least about 0.1 PPM. Gallic catechin and epigallocatechin are optimized to have a total composition of at least about 60% of the total four catechin classes, wherein epigallocatechin has a composition of at least about 45% of the total four catechin classes.
[0266] In some embodiments, the minimum bactericidal concentration (MBC) of the latex of croton, preferably the filtered latex of croton, and preferably the filtered latex of Müll.Arg. croton is about 6.25 (% vol. / vol.), about 12.5 (% vol. / vol.), about 25 (% vol. / vol.), about 50 (% vol. / vol.), or a range between any two of these values. In some embodiments, the latex of croton, preferably the filtered latex of croton, and preferably the filtered latex of Müll.Arg. croton has an MBC of about 6.25 (% vol. / vol.) to about 50 (% vol. / vol.).
[0267] Some embodiments of this document relate to a hydrogel formulation that further comprises one or more other therapeutic ingredients. In embodiments, the hydrogel formulation comprises a therapeutically effective amount of latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of croton tiglium (Müll. Arg. croton tiglium). In embodiments, the hydrogel formulation is suitable for topical application or as a topical hydrogel formulation.
[0268] Excipients must be "acceptable" in the sense that they are compatible with other components of the formulation and harmless to the recipient. Small amounts of known, well-characterized excipient components will be used that will not cause irritation or sensitization or reduce the efficacy of AB-101 when used topically or in a wound. The correct formulation of a hydrogel formulation depends on the chosen route of administration. Any known techniques and excipients may be used where appropriate and in accordance with the understanding in the art. The hydrogel formulations disclosed herein can be manufactured in any manner known in the art.
[0269] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, astragalus gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methylcellulose, including eutectic solvents, eutectic-based ionic liquids, or ionic liquids. Hydrogel formulations may additionally include: lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; and preservatives such as methylparaben and propylparaben.
[0270] The compositions include those suitable for topical application (including, for example, dermis, oral mucosa, buccal, sublingual, intraocular, and wound oral cavity), although the most suitable route may depend, for example, on the recipient's condition and limitations. The compositions can be readily available in unit dosage forms and can be prepared by any method known in the pharmaceutical field. Typically, these methods involve combining the latex of the Peruvian croton disclosed herein, preferably a filtered latex of Peruvian croton, preferably a filtered latex of Müll. Arg. Peruvian croton (wherein the composition contains at least a component concentration of the latex of Peruvian croton, preferably a component concentration of the filtered latex of Peruvian croton, preferably a component concentration of the filtered latex of Müll. Arg. Peruvian croton) (“active ingredient”) with a carrier constituting one or more auxiliary ingredients. Typically, the compositions are prepared by uniformly and closely binding the active ingredient with a liquid carrier or a subdivided solid carrier, or both, and then, if desired, shaping the product into the desired composition.
[0271] The hydrogel formulations disclosed herein can be applied topically, i.e., by non-systemic application. This includes applying the compounds disclosed herein externally to the skin surface and / or wounded oral cavity, achieving a therapeutically effective amount in the skin (e.g., epidermis, dermis, and / or wounded oral cavity). In embodiments, topical application or application of the hydrogel formulation does not result in systemic application or systemic exposure of the patient to croton oil.
[0272] Preferred unit-dose pharmaceutical compositions are pharmaceutical compositions containing an effective dose or appropriate portion of an active ingredient as described below.
[0273] The hydrogel formulation can be formulated in unit dosage forms. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human subjects and other mammals, each unit containing a calculated predetermined amount of active substance, which, when combined with suitable pharmaceutical excipients, produces the desired therapeutic effect.
[0274] Active hydrogel formulations containing latex of croton tiglium, preferably filtered latex of croton tiglium, or preferably filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least a component concentration of croton tiglium latex as a reference standard, preferably a component concentration of filtered latex of croton tiglium, or preferably a component concentration of filtered latex of Müll. Arg. croton tiglium) can be effective over a wide dosage range and can generally be administered at therapeutically effective amounts. However, it should be understood that the actual dosage of hydrogel formulations containing latex of croton tiglium, preferably filtered latex of croton tiglium, or preferably filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least a component concentration of croton tiglium latex as a reference standard, preferably a component concentration of filtered latex of croton tiglium, or preferably a component concentration of filtered latex of Müll. Arg. croton tiglium) is usually determined by the physician based on relevant circumstances including the condition to be treated, the chosen route of administration, the actual compound administered, the individual patient's age, weight and response, and the severity of the patient's symptoms.
[0275] The pharmaceutically acceptable excipient may be selected from one or more cream bases, one or more emulsifiers, one or more preservatives, one or more humectants, one or more diluents, and latex of croton tiglium, preferably filtered latex of croton tiglium, preferably filtered latex of Müll.Arg. croton tiglium.
[0276] In some embodiments, the therapeutically effective amount may vary depending on, for example, the specific purpose of the treatment, the method of administration of the compound, the patient's health and condition, and the prescribing physician's judgment. The proportion or concentration of the latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of the latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of Müll. Arg. croton tiglium) in the hydrogel formulation may vary depending on a variety of factors, including dosage, chemical characteristics (e.g., hydrophobicity), and route of administration. For example, the compound may be provided in a physiologically buffered aqueous solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges for the compound are about 1 μg / kg to about 1 g / kg body weight per day. In some embodiments, the dosage range is about 0.01 mg / kg to about 100 mg / kg body weight per day. Dosage may depend on variables such as the type and progression of the disease or disorder, the overall health status of the specific patient, the relative bioefficacy of the selected compound, the composition of the excipients, and the route of administration. The effective dose can be extrapolated from dose-response curves derived from in vitro or animal model testing systems.
[0277] The amount of composition administered to a patient will vary depending on the drug being administered, the purpose of administration (e.g., prevention or treatment), the patient's condition, the method of administration, etc. In therapeutic applications, the composition may be administered to a patient already suffering from the disease in an amount sufficient to cure or at least partially stop the symptoms of the disease and its complications.
[0278] Methods for preparing hydrogel formulations
[0279] This invention relates to a method for preparing a hydrogel formulation, the method comprising the following steps:
[0280] 1) Preparation of phase A: Propylene glycol, methylparaben and propylparaben are combined to form phase A, and then the phase A is mixed and heated at a first temperature of about 40°C to about 70°C until phase A is clear. Once clear, the heating is removed.
[0281] 2) Preparation of phase B: Disodium ethylenediaminetetraacetate dihydrate, water, sodium benzoate and potassium sorbate are combined to form phase B, and then the phase B is mixed and heated at a second temperature of about 40°C to about 70°C until phase B is clear. Once clear, the heating is removed.
[0282] 3) Add phase B to phase A to form phase C, and stir at a first stirring rate of about 500 rpm to about 1000 rpm;
[0283] 4) Add to the stirred C phase 50 PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) to form phase D, and stirred at a second stirring rate of about 500 rpm to about 1000 rpm for, for example, about 3 minutes.
[0284] 5) Preparation of E phase: Caprylic / capric triglyceride and SEPINEO TM P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) are combined and then mixed until homogeneous;
[0285] 6) Add phase E to phase D to form phase F, and stir at a third stirring rate of about 500 rpm to about 1000 rpm for about 3 minutes.
[0286] 7) Allow the F phase to cool to a third temperature below approximately 45°C;
[0287] 8) Add Peruvian croton latex, preferably Peruvian croton filtered latex, preferably Müll.Arg. Peruvian croton filtered latex (wherein the composition contains at least the component concentration of Peruvian croton latex of the reference standard, preferably the component concentration of Peruvian croton filtered latex, preferably the component concentration of Müll.Arg. Peruvian croton filtered latex) to phase F to form phase G, and stir at a fourth stirring rate of about 500 rpm to about 1000 rpm for, for example, about 5 minutes.
[0288] 9) Add dimethyl silicone oil to phase G and stir at a fifth stirring rate of about 500 rpm to about 1000 rpm for about 2 minutes to form the hydrogel formulation.
[0289] In certain embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation comprises propylene glycol in the amount of about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, about 5% to about 6%, or values within one of these ranges. Specific examples may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or any range between these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 5% propylene glycol. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 4% propylene glycol. All of the above represent weight percentages of the resulting hydrogel formulation.
[0290] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains methylparaben in amounts of about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, and about 0.05% to about 0. 0.35%, about 0.05% to about 0.3%, about 0.05% to about 0.25%, about 0.05% to about 0.2%, about 0.05% to about 0.15%, about 0.05% to about 0.1%, about 0.1% to about 0.45%, about 0.15% to about 0.4%, about 0.2% to about 0.35%, about 0.25% to about 0.30%, about 0.05% to about 0.25%, about 0.075% to about 0.225%, about 0.1% to about 0.2%, about 0.125% to about 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, or a range of any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.15% methylparaben. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.1% methylparaben. All of the above represent weight percentages of the resulting hydrogel formulation.
[0291] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains propylparaben in amounts of about 0.005% to about 0.05%, about 0.01% to about 0.05%, about 0.015% to about 0.05%, about 0.02% to about 0.05%, about 0.025% to about 0.05%, about 0.03% to about 0.05%, about 0.035% to about 0.05%, about 0.04% to about 0.05%, about 0.045% to about 0.05%, about 0.005% to about 0.045%, about 0.005% to about 0.04%, about 0.005% to about 0.035%, about 0.005% to about 0.03%, about 0.005% to about 0.025%, about 0.005% to about 0.02%, about 0.005% to about 0.015%, about 0.005% to about 0.01%, about 0.01% to about 0.045%, about 0.02% to about 0.04%, about 0.025% to about 0.035%, about 0.02% to about 0.04%, about 0.015% to about 0.045%, or values within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.015%, about 0.02%, about 0.025%, about 0.03%, about 0.035%, about 0.04%, about 0.045%, about 0.05%, or a range of any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.02% propylparaben. All of the above represent weight percentages of embodiments of the obtained hydrogel formulation.
[0292] In some embodiments of the method for preparing the hydrogel formulation, the first temperature is a value within one of the ranges of about 40°C to about 70°C, about 45°C to about 65°C, about 50°C to about 60°C. In some embodiments of the method for preparing the hydrogel formulation, the first temperature is about 55°C.
[0293] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains disodium ethylenediaminetetraacetate dihydrate in amounts of about 0.05% to about 0.5%, about 0.1% to about 0.5%, about 0.15% to about 0.5%, about 0.2% to about 0.5%, about 0.25% to about 0.5%, about 0.3% to about 0.5%, about 0.35% to about 0.5%, about 0.4% to about 0.5%, about 0.45% to about 0.5%, about 0.05% to about 0.45%, about 0.05% to about 0.4%, or about 0.05% to about 0.05%. The values are approximately 0.35%, approximately 0.05% to approximately 0.3%, approximately 0.05% to approximately 0.25%, approximately 0.05% to approximately 0.2%, approximately 0.05% to approximately 0.15%, approximately 0.05% to approximately 0.1%, approximately 0.1% to approximately 0.45%, approximately 0.15% to approximately 0.4%, approximately 0.2% to approximately 0.35%, approximately 0.25% to approximately 0.30%, approximately 0.05% to approximately 0.25%, approximately 0.075% to approximately 0.225%, approximately 0.1% to approximately 0.2%, approximately 0.125% to approximately 0.175%, or values within one of these ranges. Specific examples may include about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.2%, about 0.225%, about 0.25%, about 0.275%, about 0.3%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.15% disodium ethylenediaminetetraacetate dihydrate. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.10% disodium ethylenediaminetetraacetate dihydrate. All of the above represent weight percentages of embodiments of the obtained hydrogel formulation.
[0294] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains water in amounts of about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 20% to about 75%, about 20% to about 70%, about 20% to about 65%, about 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, about 20% to about 25%, about 25% to about 75%, about 30% to about 70%, about 35% to about 65%, about 40% to about 60%, about 45% to about 55%, or values within one of these ranges. Specific examples may include about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 60%, about 75%, about 80%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 43.38% water. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 33.38% water. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 40.38% water. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 38.38% water. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 40.7% water. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains approximately 39% water. All of the above represent weight percentages of the resulting hydrogel formulation.
[0295] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains sodium benzoate in an amount of about 0.005% to about 0.1%, about 0.1% to about 1%, about 0.05% to about 0.5%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.45%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.40% sodium benzoate. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.45% sodium benzoate. All of the above represent weight percentages of the resulting hydrogel formulation.
[0296] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains potassium sorbate in an amount of about 0.005% to about 0.1%, about 0.1% to about 1%, about 0.05% to about 0.5%, or a value within one of these ranges. Specific examples may include about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.45%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 0.45% potassium sorbate. All of the above represent weight percentages of the resulting hydrogel formulation.
[0297] In some embodiments of the method for preparing the hydrogel formulation, the second temperature is a value within one of the ranges of about 40°C to about 70°C, about 45°C to about 65°C, about 50°C to about 60°C. In some embodiments of the method for preparing the hydrogel formulation, the second temperature is about 55°C.
[0298] In some embodiments of the method for preparing the hydrogel formulation, the first stirring rate is a value within one of the following ranges: about 500 rpm to about 1000 rpm, about 500 rpm to about 900 rpm, about 500 rpm to about 800 rpm, about 500 rpm to about 700 rpm, about 500 rpm to about 600 rpm, about 600 rpm to about 700 rpm, about 600 rpm to about 800 rpm, about 600 rpm to about 900 rpm, about 600 rpm to about 1000 rpm. In some embodiments of the method for preparing the hydrogel formulation, the first stirring rate is about 600 rpm.
[0299] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation comprises The amount of 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) is about 0.5% to about 5%, about 1% to about 3%, 0.5% to about 2%, about 0.05% to about 0.2%, about 0.25% to about 1.25%, about 0.01% to about 0.1%, about 0.001% to about 0.01%, about 0.005% to about 0.02%, or a value within one of these ranges. Specific examples may include about 0.001%, about 0.004%, about 0.005%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or a range of any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation comprises The amount of 50PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) is about 2%. All of the above represent weight percentages of the hydrogel formulation obtained in the embodiments.
[0300] In some embodiments of the method for preparing the hydrogel formulation, the second stirring rate is a value within one of the following ranges: about 500 rpm to about 1000 rpm, about 500 rpm to about 900 rpm, about 500 rpm to about 800 rpm, about 500 rpm to about 700 rpm, about 500 rpm to about 600 rpm, about 600 rpm to about 700 rpm, about 600 rpm to about 800 rpm, about 600 rpm to about 900 rpm, about 600 rpm to about 1000 rpm. In some embodiments of the method for preparing the hydrogel formulation, the second stirring rate is about 600 rpm.
[0301] In certain embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation comprises caprylic / capric triglyceride in an amount of about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, about 5% to about 6%, or a value within one of these ranges. Specific examples may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 5% caprylic / capric triglyceride. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 7% caprylic / capric triglyceride. All of the above represent weight percentages of the embodiments of the resulting hydrogel formulation.
[0302] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains SEPINEO. TMThe amount of P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 0.5% to about 10%, about 1% to about 10%, about 1.5% to about 10%, about 2% to about 10%, about 2.5% to about 10%, about 3% to about 10%, about 3.5% to about 10%, about 4% to about 10%, about 4.5% to about 10%, about 5% to about 10%, and about 5%. 5% to about 10%, about 6% to about 10%, about 6.5% to about 10%, about 7% to about 10%, about 7.5% to about 10%, about 8% to about 10%, about 8.5% to about 10%, about 9% to about 10%, about 9.5% to about 10%, about 0.5% to about 9.5%, about 0.5% to about 9%, about 0.5% to about 8.5%, about 0.5% to about 8%, about 0.5% to about 7.5%. %, about 0.5% to about 7%, about 0.5% to about 6.5%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1% %, about 1% to about 9.5%, about 1.5% to about 9%, about 2% to about 8.5%, about 0.5% to about 8%, about 3% to about 7.5%, about 3.5% to about 7%, about 4% to about 6.5%, about 4.5% to about 6%, about 5% to about 5.5%, about 1% to about 5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or values within one of these ranges. Specific examples may include about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains SEPINEO. TM The amount of P600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 3.3%. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains SEPINEO. TM The amount of P600 (acrylamide / acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is about 4.0%. All of the above represent weight percentages of the hydrogel formulation obtained in the embodiments.
[0303] In some embodiments of the method for preparing the hydrogel formulation, the third stirring rate is a value within one of the following ranges: about 500 rpm to about 1000 rpm, about 500 rpm to about 900 rpm, about 500 rpm to about 800 rpm, about 500 rpm to about 700 rpm, about 600 rpm to about 700 rpm, about 600 rpm to about 800 rpm, about 600 rpm to about 900 rpm, about 600 rpm to about 1000 rpm. In some embodiments of the method for preparing the hydrogel formulation, the third stirring rate is about 700 rpm. In some embodiments of the method for preparing the hydrogel formulation, the third stirring rate is about 700 rpm.
[0304] In some embodiments of the method for preparing a hydrogel formulation, the third temperature is a value below about 25°C, below about 30°C, below about 35°C, below about 40°C, below about 45°C, or within one of these ranges. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is below about 25°C. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is below about 30°C. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is below about 35°C. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is below about 40°C. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is below about 45°C. In some embodiments of the method for preparing a hydrogel formulation, the third temperature is about 20°C.
[0305] In some embodiments of the method for preparing the hydrogel formulation, the amount of the resulting hydrogel formulation comprising croton latex, preferably croton filtered latex, preferably Müll. Arg. croton filtered latex (wherein the composition contains at least the component concentration of croton latex of the reference standard, the component concentration of croton filtered latex of croton, and the component concentration of Müll. Arg. croton filtered latex of croton) is about 5% to about 80%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 5% to about 75%, about 5% to about 70%, about 5% to about 65%, about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about 75%, about 15% to about 70%, about 20% to about 65%, about 25% to about 60%, about 30% to about 55%, about 35% to about 55%, about 40% to about 50%, or values within one of these ranges. Specific examples may include about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the hydrogel formulation comprises about 40% latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of croton tiglium latex of the reference standard, preferably the component concentration of filtered latex of croton tiglium, and preferably the component concentration of filtered latex of Müll. Arg. croton tiglium). In some embodiments of the method for preparing the hydrogel formulation, the hydrogel formulation comprises about 50% latex of croton tiglium, preferably filtered latex of croton tiglium, and preferably filtered latex of Müll. Arg. croton tiglium (wherein the composition contains at least the component concentration of croton tiglium latex of the reference standard, preferably the component concentration of filtered latex of croton tiglium, and preferably the component concentration of filtered latex of Müll. Arg. croton tiglium).In some embodiments of the method for preparing the hydrogel formulation, the amount of the resulting hydrogel formulation comprising Peruvian croton latex, preferably Peruvian croton filtered latex, and preferably Müll. Arg. Peruvian croton filtered latex (wherein the composition contains at least the component concentration of Peruvian croton latex as a reference standard, preferably the component concentration of Peruvian croton filtered latex, and preferably the component concentration of Müll. Arg. Peruvian croton filtered latex) is about 43%. In some embodiments of the method for preparing the hydrogel formulation, the amount of the resulting hydrogel formulation comprising Peruvian croton latex, preferably Peruvian croton filtered latex, and preferably Müll. Arg. Peruvian croton filtered latex (wherein the composition contains at least the component concentration of Peruvian croton latex as a reference standard, preferably the component concentration of Peruvian croton filtered latex, and preferably the component concentration of Müll. Arg. Peruvian croton filtered latex) is about 45%. The percentages described above are relative to compositions made from AB-101, wherein AB-101 has exemplary contents of marker compounds present in the latex as disclosed in Table 1a. For illustration, a pharmaceutical composition containing 100% AB-101 will contain at least about 110 PPM of gallocatechin, while a pharmaceutical composition containing 200% AB-101 will contain at least about 220 PPM of gallocatechin. All of the above represent weight percentages of embodiments of the resulting hydrogel formulation.
[0306] In some embodiments of the method for preparing the hydrogel formulation, the fourth stirring rate is a value within one of the following ranges: about 500 rpm to about 1000 rpm, about 500 rpm to about 900 rpm, about 500 rpm to about 800 rpm, about 500 rpm to about 700 rpm, about 600 rpm to about 700 rpm, about 600 rpm to about 800 rpm, about 600 rpm to about 900 rpm, about 600 rpm to about 1000 rpm. In some embodiments of the method for preparing the hydrogel formulation, the fourth stirring rate is about 700 rpm.
[0307] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation comprises dimethyl silicone oil in the amounts of about 0.5% to about 10%, about 1% to about 10%, about 1.5% to about 10%, about 2% to about 10%, about 2.5% to about 10%, about 3% to about 10%, about 3.5% to about 10%, about 4% to about 10%, about 4.5% to about 10%, about 5% to about 10%, about 5.5% to about 10%, about 6% to about 10%, about 6.5% to about 10%, about 7% to about 10%, about 7.5% to about 10%, about 8% to about 10%, about 8.5% to about 10%, about 9% to about 10%, about 9.5% to about 10%, about 0.5% to about 9.5%, about 0.5% to about 9%, about 0.5% to about 8.5%, about 0.5% to about 8%, and about 0.5% to about 7%. 5%, about 0.5% to about 7%, about 0.5% to about 6.5%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1%, about 1% to about 9.5%, about 1.5% to about 9%, about 2% to about 8.5%, about 0.5% to about 8%, about 3% to about 7.5%, about 3.5% to about 7%, about 4% to about 6.5%, about 4.5% to about 6%, about 5% to about 5.5%, about 1% to about 5%, about 1.5% to about 4.5%, about 2% to about 4%, about 2.5% to about 3.5%, or values within one of these ranges. Specific examples may include about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 2% dimethyl silicone oil. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 2.5% dimethyl silicone oil. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation contains about 3% dimethyl silicone oil. All of the above represent weight percentages of the embodiments of the resulting hydrogel formulation.
[0308] In some embodiments of the method for preparing the hydrogel formulation, the viscosity of the dimethyl silicone oil is approximately 175 cSt to approximately 525 cSt, approximately 200 cSt to approximately 525 cSt, approximately 225 cSt to approximately 525 cSt, approximately 250 cSt to approximately 525 cSt, approximately 275 cSt to approximately 525 cSt, approximately 300 cSt to approximately 525 cSt, approximately 325 cSt to approximately 525 cSt, approximately 350 cSt to approximately 525 cSt, approximately 375 cSt to approximately 525 cSt, approximately 400 cSt to approximately 525 cSt, approximately 425 cSt to approximately 525 cSt, approximately 450 cSt to approximately 525 cSt, approximately 475 cSt to approximately 525 cSt, approximately 500 cSt to approximately 525 cSt, approximately 175 cSt to approximately 500 cSt, approximately 175 cSt to approximately 475 cSt. cSt, approximately 175 cSt to approximately 450 cSt, approximately 175 cSt to approximately 425 cSt, approximately 175 cSt to approximately 400 cSt, approximately 175 cSt to approximately 375 cSt, approximately 175 cSt to approximately 350 cSt, approximately 175 cSt to approximately 325 cSt, approximately 175 cSt to approximately 300 cSt, approximately 175 cSt to approximately 275 cSt, approximately 175 cSt to approximately 250 cSt, approximately 175 cSt to approximately 225 cSt, approximately 175 cSt to approximately 200 cSt, approximately 200 cSt to approximately 500 cSt, approximately 225 cSt to approximately 475 cSt, approximately 250 cSt to approximately 450 cSt, approximately 275 cSt to approximately 425 cSt, approximately 300 cSt to approximately 400 cSt, approximately 325 cSt to approximately 375 cSt, or values within one of these ranges. Specific examples may include about 175 cSt, about 200 cSt, about 225 cSt, about 250 cSt, about 275 cSt, about 300 cSt, about 325 cSt, about 350 cSt, about 375 cSt, about 400 cSt, about 425 cSt, about 450 cSt, about 475 cSt, about 500 cSt, about 525 cSt, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the dimethyl silicone oil has a viscosity of about 350 cSt.
[0309] In some embodiments of the method for preparing the hydrogel formulation, the fifth stirring rate is a value within one of the following ranges: about 500 rpm to about 1000 rpm, about 500 rpm to about 900 rpm, about 600 rpm to about 1000 rpm, about 700 rpm to about 1000 rpm, about 800 rpm to about 1000 rpm, about 900 rpm to about 1000 rpm. In some embodiments of the method for preparing the hydrogel formulation, the fifth stirring rate is about 900 rpm.
[0310] In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation has a pH of about 3.0 to about 7.0, about 3.5 to about 7.0, about 4.0 to about 7.0, about 4.5 to about 7.0, about 5.0 to about 7.0, about 5.5 to about 7.0, about 6.0 to about 7.0, about 6.5 to about 7.0, about 3.0 to about 6.5, about 3.0 to about 6.0, about 3.0 to about 5.5, about 3.0 to about 5, about 3.0 to about 4.5, about 3.0 to about 4, about 3.0 to about 3.5, about 3.0, about 3.1, about 3.2, or about 3.3. The pH values are approximately 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, or a range between any two of these values. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation has a pH of approximately 4.0 to approximately 6.7. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation has a pH of about 3.0 to about 4.0. In some embodiments of the method for preparing the hydrogel formulation, the resulting hydrogel formulation has a pH of about 5.5 to about 6.5.
[0311] How to use
[0312] This invention relates to a method for treating a skin condition in a subject, the method comprising topically applying a therapeutically effective amount of the hydrogel formulation disclosed herein to the subject.
[0313] The present invention also relates to a method for treating a skin condition in a subject, the method comprising topically applying to the subject a therapeutically effective amount of the hydrogel formulation disclosed herein, wherein the therapeutically effective amount contains at least a component concentration of the latex of the Peruvian croton plantarum disclosed herein as a reference standard, preferably a component concentration of the filtered latex of the Peruvian croton plantarum, and preferably a component concentration of the filtered latex of the Müll. Arg. Peruvian croton plantarum.
[0314] The present invention also relates to a method of treating a skin condition in a subject, the method comprising topically applying a therapeutically effective amount of the hydrogel formulation disclosed herein, wherein the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, comprises one or more compounds selected from gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin, and combinations thereof. Each of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin may be present in the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, in the form of gallocatechin, epigallocatechin, catechin, epicatechin, taspine, and dimethyl cedryatin, in amounts found in Table 1a or paragraphs
[0134] -
[0139] , or any combination of these amounts, in the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium. In some embodiments, the latex of Peruvian croton, preferably filtered latex of Peruvian croton, and preferably filtered latex of Müll.Arg. Peruvian croton has the PDI of the embodiments disclosed herein.
[0315] This document also provides hydrogel formulations disclosed herein for use as pharmaceuticals. In some embodiments, the latex of Peruvian croton, preferably filtered latex of Peruvian croton, and preferably filtered latex of Müll. Arg. Peruvian croton has the PDI of the embodiments disclosed herein.
[0316] This article also provides the hydrogel formulation disclosed herein, which is used as a medicine for treating skin conditions.
[0317] This article also provides the uses of the hydrogel formulations disclosed herein as medicines for the treatment of skin conditions.
[0318] Also provided are hydrogel formulations disclosed herein, wherein the latex of croton tiglium, preferably filtered latex of croton tiglium, preferably filtered latex of croton tiglium (Müll. Arg. croton tiglium), contains a component concentration of the reference standard of croton tiglium disclosed herein, a component concentration of the filtered latex of croton tiglium, preferably a component concentration of the filtered latex of croton tiglium, preferably a component concentration of the filtered latex of croton tiglium (Müll. Arg. croton tiglium), and is used to prepare a medicament for treating skin conditions. In some embodiments, the latex of croton tiglium, preferably filtered latex of croton tiglium, preferably filtered latex of croton tiglium (Müll. Arg. croton tiglium) has the PDI of the embodiments disclosed herein.
[0319] The use of the hydrogel formulations disclosed herein is also provided, wherein the latex of croton tiglium, preferably filtered latex of croton tiglium, preferably filtered latex of croton tiglium Müll.Arg. croton tiglium, contains the component concentration of the reference standard of croton tiglium disclosed herein, preferably the component concentration of filtered latex of croton tiglium Müll.Arg. croton tiglium, preferably the component concentration of filtered latex of croton tiglium Müll.Arg. croton tiglium, and is used to prepare skin conditions. In some embodiments, the latex of croton tiglium, preferably filtered latex of croton tiglium Müll.Arg. croton tiglium, preferably the component concentration of filtered latex of croton tiglium Müll.Arg. croton tiglium has the PDI of the embodiments disclosed herein.
[0320] This document also provides a method for treating a skin condition in a subject in need, the method comprising topically applying to the subject a therapeutically effective amount of the hydrogel formulation disclosed herein, wherein the hydrogel formulation comprises a component concentration of the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, containing a reference standard of croton tiglium disclosed herein, preferably a component concentration of the filtered latex of croton tiglium, preferably a component concentration of the filtered latex of Müll.Arg. croton tiglium. In some embodiments, the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium has the PDI of the embodiments disclosed herein.
[0321] This document also provides a method for achieving a therapeutic effect in a patient, the method comprising administering a therapeutically effective amount of the hydrogel formulation disclosed herein, wherein the hydrogel formulation comprises a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of croton tiglium (Müll.Arg.), containing a component concentration of a reference standard of croton tiglium latex, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of croton tiglium (Müll.Arg.). In some embodiments, the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of croton tiglium (Müll.Arg.), has the PDI of the embodiments disclosed herein.
[0322] In some embodiments, the skin condition is selected from atopic dermatitis, epidermolysis bullosa, impetigo, psoriasis, wounds, skin colonized by pathogens, atopic dermatitis in patients infected with Staphylococcus aureus, atopic dermatitis in patients infected with methicillin-resistant Staphylococcus aureus (MRSA), atopic dermatitis in patients infected with mupirocin-resistant MRSA, epidermolysis bullosa in patients infected with Staphylococcus aureus, epidermolysis bullosa in patients infected with methicillin-resistant Staphylococcus aureus (MRSA), epidermolysis bullosa in patients infected with mupirocin-resistant MRSA, epidermolysis bullosa in patients infected with Streptococcus pyogenes, and epidermolysis bullosa in patients infected with Pseudomonas aeruginosa. The group consists of the following: impetigo in patients with Staphylococcus aureus infection, impetigo in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection, impetigo in patients with mupirocin-resistant MRSA infection, impetigo in patients with Streptococcus pyogenes infection, psoriasis in patients with Staphylococcus aureus infection, psoriasis in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection, psoriasis in patients with mupirocin-resistant MRSA infection, wounds in patients with Staphylococcus aureus infection, wounds in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection, wounds in patients with mupirocin-resistant MRSA infection, wounds in patients with Streptococcus pyogenes infection, wounds in patients with Pseudomonas aeruginosa infection, and combinations thereof.
[0323] In some implementations, the skin condition is atopic dermatitis.
[0324] In some embodiments, the skin condition is bullous epidermolysis.
[0325] In some implementations, the skin condition is impetigo.
[0326] In some implementations, the skin condition is psoriasis.
[0327] In some implementations, the skin condition is a wound.
[0328] In some embodiments, the skin condition is skin colonized with pathogens.
[0329] In some embodiments, the pathogen is selected from the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), mupirocin-resistant MRSA, and combinations thereof.
[0330] In some embodiments, the pathogen is Staphylococcus aureus.
[0331] In some embodiments, the pathogen is methicillin-resistant Staphylococcus aureus (MRSA).
[0332] In some embodiments, the pathogen is mupirocin MRSA.
[0333] In some embodiments, the skin condition is atopic dermatitis in patients with Staphylococcus aureus infection.
[0334] In some embodiments, the skin condition is atopic dermatitis in patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
[0335] In some embodiments, the skin condition is atopic dermatitis in patients with mupirocin-associated MRSA infection.
[0336] In some embodiments, the skin condition is bullous epidermolysis in patients with Staphylococcus aureus infection.
[0337] In some embodiments, the skin condition is bullous epidermolysis in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection.
[0338] In some embodiments, the skin condition is bullous epidermolysis in patients with anmupirocin-associated MRSA infection.
[0339] In some embodiments, the skin condition is bullous epidermolysis in patients with Streptococcus pyogenes infection.
[0340] In some embodiments, the skin condition is bullous epidermolysis in patients with Pseudomonas aeruginosa infection.
[0341] In some embodiments, the skin condition is impetigo in patients with Staphylococcus aureus infection.
[0342] In some embodiments, the skin condition is impetigo in patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
[0343] In some embodiments, the skin condition is impetigo in patients with anmupirocin-associated MRSA infection.
[0344] In some embodiments, the skin condition is impetigo in patients with Streptococcus pyogenes infection.
[0345] In some embodiments, the skin condition is psoriasis in patients with Staphylococcus aureus infection.
[0346] In some embodiments, the skin condition is psoriasis in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection.
[0347] In some embodiments, the skin condition is psoriasis in patients with anmopirox MRSA infection.
[0348] In some embodiments, the skin condition is a wound in a patient with a Staphylococcus aureus infection.
[0349] In some embodiments, the skin condition is a wound in a patient infected with methicillin-resistant Staphylococcus aureus (MRSA).
[0350] In some embodiments, the skin condition is a wound in a patient with an antimupirocin-associated MRSA infection.
[0351] In some embodiments, the skin condition is a wound in a patient with a Streptococcus pyogenes infection.
[0352] In some embodiments, the skin condition is a wound in a patient with a Pseudomonas aeruginosa infection.
[0353] This document also provides a method for preventing skin conditions in subjects in need, the method comprising contacting the subject's skin with the hydrogel formulation disclosed herein, wherein the hydrogel formulation contains a component concentration of a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, containing a reference standard of croton tiglium disclosed herein, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of Müll.Arg. croton tiglium. In some embodiments, the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium has the PDI of the embodiments disclosed herein.
[0354] This document also provides a method for maintaining overall skin health in subjects in need, the method comprising contacting the subject's skin with the hydrogel formulation disclosed herein, wherein the hydrogel formulation contains a component concentration of a latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium, containing a reference standard of croton tiglium disclosed herein, preferably a component concentration of a filtered latex of croton tiglium, preferably a component concentration of a filtered latex of Müll.Arg. croton tiglium. In some embodiments, the latex of croton tiglium, preferably a filtered latex of croton tiglium, preferably a filtered latex of Müll.Arg. croton tiglium has the PDI of the embodiments disclosed herein.
[0355] The hydrogel formulation can be applied in various ways, such as topically (including, for example, the dermis, oral mucosa, buccal, sublingual, and intraocular). Furthermore, the route of application may vary depending on the condition and its severity.
[0356] The hydrogel formulation can be applied in various ways, such as topically (including, for example, the dermis, oral mucosa, buccal, sublingual, intraocular, and wounded oral cavity). The specific dosage level for any particular patient will depend on a variety of factors, including the activity of the particular compound used, age, weight, general health, sex, diet, time of application, route of application, excretion rate, drug combination, the exact barrier being treated, and the severity of the indication or condition being treated. Furthermore, the route of application may vary depending on the condition and its severity.
[0357] The hydrogel formulation of the present invention can be applied once daily, twice daily, three times daily, four times daily, five times daily, six times daily, seven times daily, eight times daily, nine times daily, ten times daily, or a range between these values. In some embodiments, the hydrogel formulation is applied once daily. In some embodiments, the hydrogel formulation is applied twice daily. In some embodiments, the hydrogel formulation is applied three times daily. In some embodiments, the hydrogel formulation is applied 1 to 3 times daily. In some embodiments, the hydrogel formulation is applied until the skin condition subsides, disappears, or is treated.
[0358] The hydrogel formulation of this invention can be used continuously, every 15 minutes, 30 minutes, 1 hour (hr.), 1 1 / 2 hours, 2 hours, 2 1 / 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 2... The treatment may be administered at 3, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 weeks, or within a range of these values. In some embodiments, the treatment lasts for 24 weeks. In a particular embodiment, the treatment lasts for 2 weeks. In a particular embodiment, the treatment lasts for 4 weeks. In some embodiments, the treatment continues until the skin condition subsides, disappears, or is treated.
[0359] Treatment for skin conditions can last for 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, or a range of these values. In some embodiments, the treatment lasts for 2 weeks. In some embodiments, the treatment continues until the skin condition subsides, disappears, or is cured.
[0360] Treatment for the skin condition can continue until the target lesion completely disappears.
[0361] The doctor prescribing the medication may decide whether to continue the treatment for the skin condition.
[0362] In some embodiments, the hydrogel formulation of the present invention can be directly applied topically to the skin condition.
[0363] In some embodiments, the hydrogel formulation of the present invention can be directly applied topically to lesions caused by skin conditions.
[0364] In some embodiments, the dosage is a suitable amount of the hydrogel formulation of the present invention to cover the target area of the skin lesion. The hydrogel formulation is applied to each skin lesion once, twice, or more daily. Multiple applications may be made for a batch of lesions. The hydrogel formulation is gently rubbed into the skin lesion site (for approximately 15 seconds) until a thin layer of the hydrogel formulation is formed.
[0365] In some embodiments, the hydrogel formulation of the present invention is first applied to a bandage (e.g., gauze) and then applied to the skin lesion. The treated bandage is applied to each lesion. If the bandage separates from the lesion or if the dressing has been worn for 24 hours, a new treated bandage can be applied. The new dressing is typically, but not always, applied daily, and may be applied up to once a week or longer. In one embodiment, the composition is administered until symptoms (e.g., skin lesions) disappear, become less noticeable, or problematic side effects occur.
[0366] In some embodiments, the hydrogel formulation has a minimum inhibitory concentration (MIC) of at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.25%, at least about 0.5%, at least about 0.75%, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100%.
[0367] Examples - AB-101 Hydrogel Formulation and Properties
[0368] For the drug to be effective, it must be easily released from the hydrogel carrier, and the hydrogel carrier should not enhance the penetration or permeation of the bioactive ingredient into the skin. Minimizing skin penetration maximizes the amount of AB-101 retained on the affected area of the skin to resolve the dermatitis. The AB-101 drug substance (CPL) should have a low partition potential to minimize systemic absorption and maximize the safety of AB-101 use.
[0369] As shown in Table 3a, a series of hydrogel formulations containing progressively increasing levels of pharmaceutical-grade AB-101 were prepared, and the pH of each formulation is shown in Table 3b. The hydrogel formulations were prepared using Dow Corning. Fluid, 350 CST dimethyl silicone oil, caprylic / capric triglycerides and SEPINEO TM The P 600 copolymer forms a gel, and the dosage range of AB-101 includes addition levels of 20%, 30%, 40%, and 50%, wherein the purified water in the formulation decreases with increasing AB-101 levels. The AB-101 used in the formulation is mechanically filtered and not fractionated, maintaining the proanthocyanidins and taspine components detailed in the AB-101 fingerprint.
[0370] Table 3a - Hydrogel formulations using pharmaceutical grade AB-101
[0371]
[0372] Table 3b - pH of hydrogel formulations
[0373]
[0374] Example 1 - Release study of AB-101 from the carrier: In vitro Franz diffusion cell
[0375] The Franz diffusion cell in vitro drug release assay (IVRT) used here is a recognized industry-standard method for determining the release of a topically applied drug from its carrier (USP Chapter 1724, USP 36 / NF31, 2013; Ueda et al., 2009; Li & Rahn, 1993). This assay uses... The membrane (Pall Corporation SKU 66394) has been shown to be effective in confirming the in vivo release of drugs from their carriers (Thakker KD, Chern WH, 2003, Development and validation of in vitro release tests for semisolid dosage forms - case study Dissolution Technologies. May; 10(2):10-6). To determine the carrier release flux (the amount of permeate or test material per unit area per unit time per unit area) of PACs (catechin, epicatechin, gallocatechin, epigallocatechin) and taspine of AB-101, the amount of each PAC and taspine diffused through the membrane, i.e., the flux, was quantified using existing analytical LC-MS / MS methods.
[0376] Table 4 - In vitro drug release assays using AB-101 Franz diffusion cell flux calculated using LC-MS / MS.
[0377]
[0378] Example 2 - AB-101 Skin Permeation Study: In Vitro Franz Diffusion Cell
[0379] The Franz diffusion cell in vitro drug release test (IVRT) used here is a recognized industry-standard method for determining the skin penetration of products for topical application (USP Chapter 1724, USP 36 / NF31, 2013; Ueda et al., 2009; Li & Rahn, 1993). Furthermore, this test utilizes a Strat-M membrane (Millipore Sigma SKU SKBM02560), which has been shown to predict in vivo skin penetration results (Flaten GE, Palac Z, Engesland A, ...). J, -Basnet N, 2015, In vitroskin models as a tool in optimization of drug formulation (Eur J PharmSci. 75:10-24). To determine the transdermal flux (the amount of permeate or test material passing through the membrane per unit area per unit time) of PACs (catechins, epicatechins, gallocatechins, epigallocatechins) and taspine in AB-101, the amount of each PAC and taspine diffusing through the membrane, i.e., the flux, was quantified using existing analytical LC-MS / MS methods.
[0380] Franz diffusion cell in vitro drug penetration test data (Table 5) demonstrate that PAC and taspine of AB-101 exhibit low flux or low diffusion compared to the total amount of these compounds in 100% AB-101 liquid. Low flux or low diffusion of PAC and taspine of AB-101 was demonstrated for all tested forms of AB-101; for each of the four tested AB-101 hydrogel formulations (AB-101 concentrations in the hydrogel delivery material were 20%, 30%, 40%, and 50%, respectively). These Franz diffusion cell in vitro drug penetration results predict low in vivo penetration of AB-101 into the skin.
[0381] Table 5: Skin penetration test results of AB-101 Franz diffusion cell calculated using LC-MS / MS flux.
[0382]
[0383] The results showed that AB-101PAC and taspinine exhibited low flux or diffusion across intact synthetic membranes, predicting low permeability of AB-101 in human skin and therefore low transdermal levels.
[0384] Table 5 presents novel and unexpected results enhancing the efficacy and safety of hydrogels containing AB-101. The permeability of AB-101 transdermal flux actually decreased with increasing AB-101 dosage. This was unexpected. The conventional expectation was that permeability would increase with increasing AB-101 dosage. This is evidence that the 100% AB-101 dosage level had the highest transdermal flux or highest permeability. In fact, at 50% of the highest dosage level, the permeability of PAC was at its lowest, and permeability was negligible. An inverse relationship also held for the alkaloid taspine, where permeability decreased by 81% when the AB-101 dosage increased to 50%.
[0385] The hydrogel completely transforms the efficacy of AB-101. This offers significant performance advantages. Lower permeability means significantly greater quantities of AB-101 can be used to treat skin conditions, enhancing efficacy while maximizing AB-101 delivery. This minimizes the potential for antimicrobial resistance development by maximizing the targeting of pathogens, particularly MRSA, as demonstrated by time-kill kinetic assays. These assays show that maximum pathogen killing is achieved at 50% of the dose level. In addition to the safety benefits associated with minimizing the potential for antimicrobial resistance development, safety is further enhanced at higher AB-101 levels due to lower transdermal flux, indicating that AB-101 will remain on the skin rather than be absorbed systemically.
[0386] Example 3 - AB-101 Allocation Study - In Vitro LogP
[0387] LogP is an assessment of the lipophilicity of a compound, indicating how easily a mixture can partition between an aqueous and an organic phase. The in vitro LogP test used here is a recognized industry-standard method for assessing the lipophilicity of compounds, in this case, compounds applied topically to the skin (Pollastri MP, 2010, Overview on the Rule of Five, Current protocols in pharmacology. Jun; 49(1):9-12). When a topical drug has poor lipophilicity, with a LogP rating of -1 to 2 (Table 6), the topical drug will not easily penetrate or disperse into the skin when applied to it (Tshepelevitsh S, Kadam SA, Darnell A, Bobacka J, Rüütel A, Haljasorg T, Leito I, 2020, LogP determination for Highly Lipophilic Hydrogen Bonding Anion Receptor Molecules, Analytica Chimica Acta. Jul 30). In order to achieve high systemic levels, topical drugs must be sufficiently permeable, which is defined as being lipophilic enough to distribute into the lipid bilayer of the skin, but not so lipophilic that once they enter the skin bilayer they are isolated there (Weng Z, Wang K, Li H, Shi Q, 2015, A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications, Oncotarget. Jul 10; 6(19):17031).Lipophilicity plays an important role in determining the distribution of drugs in the body after they are absorbed into tissues, and thus the rate of drug metabolism and excretion (Lipinski CA, 2000, Drug-like properties and the causes of poor solubility and poor permeability, Journal of pharmacological and toxicological methods. Jul 1; 44(1):235-49).
[0388] Table 6: LogP rating scale and values
[0389]
[0390] To evaluate the LogP partition coefficient of the entire AB-101 100% drug substance, a standard LogP partition coefficient test was performed on the AB-101 100% drug substance (CPL) in liquid form as the raw material. In addition, LogP partition coefficient tests were performed on five key components affecting antimicrobial activity from four different forms of AB-101 drug substance: (1) AB-101 100% drug substance in liquid form as the raw material, (2) AB-101 100% lyophilized powder resuspended in water, (3) AB-101 20% hydrogel formulation, and (4) AB-101 50% hydrogel formulation.
[0391] The following LogP partition coefficient test method was used: (a) water and n-octanol were placed in a glass separatory funnel (GSF); (b) a certain amount of each test form determined in the previous section was measured and placed in the GSF; (c) the GSF was placed in a vortex mixer to mix and disperse the test material in water or n-octanol; (d) the GSF was then left to stand overnight to reseparate it into its original water and n-octanol two phases; (e) for AB-101 100% pharmaceutical material taken in liquid form of raw material, the aqueous layer was then collected and analyzed by LCMS, and the LCMS result was compared with the known LCMS result of each test material of whole AB-101 to determine the amount of test material in water and n-octanol; (f) for all other forms, the aqueous layer was then collected and freeze-dried, the remaining powder was weighed and compared with the total amount of powder in AB-101 to determine the amount of powder in the aqueous layer, and the amount of powder in the n-octanol layer was determined by subtraction.
[0392] LogP of AB-101 100% pharmaceutical substance (CPL)
[0393] The partition assays reported below (Table 7) determined the in vitro partitioning and release of AB-101 100% pharmaceutical substance (CPL), which were tested in triplicate in three different amounts. These data report poor lipophilicity of the liquid form of AB-101 100% (CPL), as defined by the LogP analysis. Since the skin is lipophilic, these data suggest that AB-101, which is poorly lipophilic, will not easily penetrate or disperse in the skin when applied directly (Mtewa AG, Ngwira K, Lampiao F, Weisheit A, Tolo CU, 2018, Fundamental Methods in Drug Permeability, pKa, LogP and LogDx Determination, JDrug Res Dev. 4(2):2470-1009; Rolland, Y, 2011, Naturals–the return of the dragon, The Medicinal Chemist. 15-JUL-1; Martin, KR (2009), Polyphenols as dietary supplements: A double-edged sword, Nutrition and Dietary Supplements, 1. doi:10.2147 / nds.s6422). The lack of lipophilicity further demonstrates that AB-101 will not cross the skin to enter the underlying tissues or systemic circulation. AB-101's poor skin and tissue permeability suggests a limited ability to be absorbed into the skin, making it even less likely to cross the skin to reach the systemic circulation or other tissues or organs. If AB-101 does reach the systemic circulation, its poor tissue permeability means it will not accumulate in the tissues and will be excreted from the body.
[0394] Table 7: LogP values for AB-101 100% (CPL) in liquid form
[0395]
[0396] LogP of AB-101's main components and other compounds
[0397] LogP was tested for five key components affecting the antimicrobial activity of AB-101 drug substance (CPL) in four different forms and for the remaining unidentified compounds of AB-101: AB-101 100% raw material liquid form (CPL), lyophilized and resuspended AB-101 100% (CPL), AB-101 20% hydrogel formulation, and AB-101 50% hydrogel formulation.
[0398] The partitioning assays reported here (Table 8) determined the in vitro partitioning and release of five key components (four PACs namely catechin, epicatechin, epigallocatechin, gallocatechin plus taspine) and the remaining components of AB-101 from four different AB-101 forms that affect antimicrobial activity: (1) AB-101 100% liquid (CPL) from AB-101 batches 0, 1, 2 and X; (2) AB-101 100% liquid (CPL) from batches 0, 1, 2 and X after being lyophilized and resuspended in water to determine the effect of these processes on partitioning in the case of using lyophilization and resuspension processes in commercial production; and (3 and 4) two AB-101 hydrogel formulations (20% AB-101 and 50% AB-101) from AB-101 batch 1. These data report poor lipophilicity of all five key AB-101 components (PAC and taspinal) and other compounds affecting antimicrobial activity, as defined by LogP analysis of all four forms tested. Since skin is lipophilic, the poorly lipophilic PAC and taspinal of AB-101, along with other compounds of AB-101, will not readily penetrate or disperse in the skin when applied directly. This lack of lipophilicity further demonstrates that the PAC and taspinal of AB-101, along with other compounds of AB-101, will not cross the skin into the underlying tissues or systemic circulation. The poor skin and tissue permeability of the PAC and taspinal of AB-101, along with other compounds of AB-101, indicates a limited ability to be absorbed into the skin, making it even less likely that they will cross the skin to reach the systemic circulation or other tissues or organs. If any of the PAC and taspinal of AB-101, along with other compounds of AB-101, does reach the systemic circulation, their poor tissue penetration means that they will not accumulate in the tissues and will be eliminated from the body.
[0399] Table 8: LogP values of five key AB-101 components affecting antimicrobial activity and the remaining compounds of AB-101 from AB-101 100% liquid (CPL), lyophilized and resuspended AB-101 100% liquid (CPL), and two AB-101 hydrogel formulations (AB-101 20% and 50%).
[0400]
[0401]
[0402] 1 The LogP values of the reference standards PAC and taspine were not significantly different from those of PAC and taspine from AB-101 tested in various forms.
[0403] 2 LogP values of reference standards from ALOGPS, ChemAxon, and Chemspider
[0404] 3 Other compounds present but not identified; calculations were based on peak areas from full chromatographic scans.
[0405] Data from 100% AB-101, AB-101 PAC, AB-101 taspine, and AB-101 hydrogel formulations support the conclusion that the chance of topical AB-101 penetrating the skin layer in any considerable amount is extremely low. The data also support the conclusion that any AB-101 that penetrates the skin is likely to be metabolized / biotransformed within the skin before having the opportunity for systemic absorption. Furthermore, given that the logP results predict little or no penetration, the likelihood of systemic absorption of AB-101 if it does penetrate the skin is also low. The logP data for the hydrogel do not provide any adverse performance factors that would alter the logP partition coefficient of AB-101 within the hydrogel matrix.
[0406] The efficacy of AB-101 in the hydrogel for eradicating harmful pathogens was confirmed in a bridging study that compared the minimum inhibitory concentration (MIC) with the level of AB-101 contained in the hydrogel (50%) by well diffusion assays performed by measuring the zone of inhibition (ZOI).
[0407] The agar diffusion assay (Remel trypsin-soybean agar-TSA) was performed on a hydrogel carrier containing AB-101. TSA plates were coated with a bacterial growth of Staphylococcus aureus ATCC 29213 or Pseudomonas aeruginosa ATCC 27853. Two 4 mm wells were drilled from each plate using a biopsy punch. The agar plates were then tare-weighed on an analytical balance, and a small amount (approximately 10 mg) of the hydrogel containing AB-101 was dispensed into one well. The density of AB 101 batch 1 was 100 μL = 102.4 mg, but for practical purposes, 100 μL = 100 mg was used. AB 101 batch 1 was diluted 1:1 with sterile DI water to prepare a 50% solution to match 50% of the AB 101 concentration in the gel. The corresponding volume of this 50% AB-101 was dispensed into the second well on the agar plate, the TSA plate was incubated overnight, and the ZOI was measured with a ruler the following day.
[0408] Table 9: Pore diffusion inhibition region of AB-101 compared to hydrogel
[0409]
[0410] The results shown in Table 9 indicate that 50% of batch 1 (control) and AB-101 hydrogels had similar ZOI, suggesting that the hydrogels are equivalent to AB-101 and that the hydrogels do not interfere with the effectiveness of AB-101 in inhibiting the growth of the two pathogens.
[0411] A bridging study was conducted to compare the relationship between the micromineral activity (MIC) of AB-101 and hydrogels containing AB-101. The aim of the study was to demonstrate that the hydrogels did not interfere with or affect the MIC properties of AB-101 after release from the support. A 50% solution was used to match the concentration of 50% AB101 in the gel.
[0412] Four strains of Staphylococcus aureus, four strains of Pseudomonas aeruginosa, and four strains of Streptococcus pyogenes were tested using the well diffusion method against 50% AB-101 batch 1 and 50% hydrogel. The strains and their MIC values for AB-101 batch 1 are listed in Table 10. For bridging studies, the weight (in mg) of hydrogel allocated to one well on the agar was determined using an analytical balance. The volume of 50% AB-101 batch 1 to be added was determined by normalizing the density of AB-101 batch 1 (i.e., 1.02 mg / μL). For example, if 17.4 mg of hydrogel was allocated to the first well, 17.1 μL of 50% AB-101 batch 1 was allocated to the second well on the plate. TSA plates were used for Staphylococcus aureus and Pseudomonas aeruginosa, while TSA + 5% defibrinated sheep blood was used for Streptococcus pyogenes.
[0413] Table 10: Study on pore diffusion bridging between AB-101 and hydrogel
[0414]
[0415]
[0416] *Normalized to the density of AB-101 batch 1, i.e., 1.02 mg / μL
[0417] Table 10 confirms that the hydrogel does not interfere with or alter the properties of AB-101. At the MIC level of AB-101, the hydrogel ZOI is essentially indistinguishable from pure 50% diluted AB-101 in Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pyogenes.
[0418] Example 4 - Liquid Bandages and Protection
[0419] The hydrogel containing 50% AB-101 is reddish-brown before application. Once applied, the hydrogel becomes translucent, a light color with a slight reddish-brown tint. The film takes approximately 3 to 4 minutes to become touch-dry. As the hydrogel dries, it becomes a glossy film, indicating that it is a liquid bandage. This liquid bandage helps seal in moisture within the hydrogel and provides a protective layer. Moisturizing is particularly beneficial for both eczema and EB. The protective film of the liquid bandage helps protect the skin from any impurities. Figure 7 The properties of the film-forming liquid bandage after application to the inner forearm were described.
[0420] Example 5 - Preparation of AB-101 hydrogel formulation
[0421] The following procedure highlights the steps required for the production of the AB-101 hydrogel formulation:
[0422] 1) Preparation of phase A: Propylene glycol, methylparaben and propylparaben are combined to form phase A. Phase A is then mixed at 55°C and heated until it becomes clear. Once clear, heating is stopped.
[0423] 2) Preparation of phase B: Combine disodium ethylenediaminetetraacetate dihydrate, water, sodium benzoate and potassium sorbate to form phase B. Then mix phase B at 55°C and heat until phase B becomes clear. Once clear, stop heating.
[0424] 3) Add phase B to phase A to form phase C, and stir at 600 rpm;
[0425] 4) Add to the stirred C phase Add 50 PG (phosphatidylcholine, lysophosphatidylcholine, propylene glycol, sunflower seed oil glycerides, ethanol, soybean fatty acids, ascorbate palmitate, D,L-α-tocopherol) to form phase D, and stir at 600 rpm for about 3 minutes.
[0426] 5) Preparation of E phase: Caprylic / capric triglyceride and SEPINEO TM P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) are combined and then mixed until homogeneous;
[0427] 6) Add phase E to phase D to form phase F, and stir at 700 rpm for about 3 minutes;
[0428] 7) Cool the F phase to 45°C or lower;
[0429] 8) Add AB-101 to phase F to form phase G, and stir at 700 rpm for about 5 minutes;
[0430] 9) Add dimethyl silicone oil to phase G and stir at 900 rpm for about 2 minutes to form AB-101 hydrogel formulation.
[0431] like Figure 8 As shown, adding dimethyl silicone oil in the final step, after hydrogel formation, yields a stable and homogeneous product. If the dimethyl silicone oil is added before hydrogel formation, the resulting product will suffer from air trapping, as... Figure 9 As shown in the image. Microscopic photograph of the hydrogel formulation ( Figure 10 This further confirms the necessity of adding dimethyl silicone oil after hydrogel formation; the photograph shows a brown color, confirming that AB-101 has been trapped in the hydrogel matrix. However, when dimethyl silicone oil is added before hydrogel formation, the microscopic photograph of the hydrogel formulation ( Figure 11 The blue color confirms that air is trapped between AB-101 and the hydrogel matrix.
[0432] Excessive stirring rate during the addition of AB-101 can cause shearing, resulting in air being trapped in the formulation. Figure 12 However, insufficient stirring rate will prevent hydrogel formation.
[0433] AB-101 should be added to phase G because of the earlier addition of AB-101 ( Figure 13 It prevents hydrogel formation.
[0434] To minimize the hydrogel formulation's contact with air, it is best to store it in an airless press bottle.
[0435] Example 6 - Study of participants with mild to moderate atopic dermatitis with or without secondary infection treated with AB-101
[0436] A randomized, double-blind, multicenter study was conducted in male or female participants with mild to moderate AD infection or no AD infection to evaluate the safety and efficacy of topical AB-101 compared to hydrogel carriers in treating male or female participants with mild to moderate AD infection or no secondary infection.
[0437] The objectives and endpoints of the study are shown in Table 11.
[0438] Table 11
[0439]
[0440]
[0441] The overall study design is shown in Table 12.
[0442] Table 12
[0443]
[0444] Study population: This study will recruit approximately 60 male / female participants aged 2 years or older with mild to moderate Alzheimer's disease (AD) with or without secondary infections.
[0445] The intervention groups and study duration are summarized in Table 13.
[0446] Table 13
[0447]
[0448] Inclusion Criteria – Participants were eligible for inclusion in the study only if they met all of the following criteria. Male / female participants aged ≥2 years on the day written informed consent / consent was provided. A clinical diagnosis of AD confirmed at least 3 months prior to the screening visit, according to the criteria of Hanifin and Rajka (1980). Mild to moderate AD, indicated by an IGA score of 2 (mild) or 3 (moderate), at screening and on day 1 prior to the application of the study intervention. AD covering at least 5% of the total BSA in the head (including the face but excluding the scalp with hair), neck, trunk (excluding the groin and genitals), or extremities at screening and day 1 (visit 1). An EASI total score of ≥3 to ≤21 at screening and day 1. A SIRS score ≥8 (group 1) or <8 (group 2). Participants received a stable regimen of all permitted oral and topical medications (continuously used for 14 days prior to day 1). Willingness to avoid the use of any topical products, cosmetics, or skin cleansers on the target lesions during the application of the study intervention. Participants must be willing to avoid applying the research intervention to skin areas outside the target lesion area. They must be willing and able to adhere to all planned visits, treatment plans, laboratory tests, lifestyle considerations, and other research procedures. Female participants are eligible to participate if they are not pregnant, not breastfeeding, and meet at least one of the following criteria: not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow contraceptive guidelines. Participants (or their legally authorized representatives, where applicable) must provide written informed consent / consent form for the study.
[0449] Exclusion Criteria – Participants were excluded from the study if any of the following criteria applied: Suffering from unstable AD, or having any ongoing need for potent topical corticosteroids to control AD signs and symptoms. Having an active systemic infection requiring antibiotic treatment. Having recently used or anticipated concurrent use of systemic or topical treatments that may alter the course of AD. Having a Fitzpatrick skin type score of 6. Having received treatment with any monoclonal antibody, TYK2, and / or JAK inhibitor within 6 months or 5 half-lives (whichever is shorter) prior to Day 1. Having received treatment for any type of cancer (excluding squamous cell carcinoma, basal cell carcinoma, or cutaneous carcinoma in situ that has been cured by cryosurgery or surgical excision alone). Having an active or potentially recurrent skin condition other than AD that may confound the assessment. Having a history of serious, progressive, or uncontrolled kidney, liver, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease, either currently present or recently (within approximately 3 months). A history of any lymphoproliferative disorder (e.g., Epstein-Barr virus-associated lymphoproliferative disorder), lymphoma, leukemia, malignancy, or signs and symptoms suggestive of current lymphatic disease (Note: Adults with adequately treated or excised non-metastatic basal or squamous cell carcinoma of the skin or cervical cancer in situ are permitted). A history of hospitalization, parenteral antimicrobial, antiviral, antiparasitic, antiprotozoal, or antifungal treatment, or a systemic (within approximately 3 months), chronic, or acute skin infection (within approximately 2 weeks) deemed clinically significant by the investigator. Use of systemic antibiotics or systemic corticosteroids within 28 days prior to screening. Use of topical antiviral, topical antibacterial, topical antifungal, or topical corticosteroids within 14 days prior to Day 1. Known inherited immunodeficiency disorders. Experience of major trauma or major surgery as determined by the investigator within 1 month prior to screening. Known allergy to any component of AB-101 or its carrier. Other acute or chronic medical or psychiatric conditions, including recent (within the past year) or voluntary suicidal ideation or behavior or laboratory abnormalities, that may increase the risk associated with study participation or administration of investigational drugs, or may interfere with the interpretation of study results and, in the investigator's judgment, render a participant unsuitable for the study. A positive WOCBP urine pregnancy test within 24 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required (Note: If 24 hours have passed between the screening pregnancy test and the first dose of the study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to begin the study intervention). Received a live or attenuated live vaccine within 30 days prior to the first dose of the study intervention. Inactivated vaccines and mRNA vaccines are permitted. Currently participating in or having participated in a study of an investigational drug or used an investigational device within 28 days prior to the first dose of the study intervention.A known history of HIV, hepatitis B, or hepatitis C infection is required (Note: HIV, hepatitis B, or hepatitis C testing is not required unless mandated by local health authorities). Researchers directly involved in the study, their field staff and their families, and field staff supervised by investigators are ineligible. A history of alcohol or drug abuse within the six months prior to screening, which researchers believe will hinder participation in the study. A history or current evidence of any medical condition, treatment, or laboratory abnormality that researchers believe may confound the results of this study, interfere with the participant's participation in the entire study process, or be in the participant's best interests.
[0450] Discussion of research design
[0451] The proposed Phase 2a, multicenter, randomized, double-blind, vector-controlled, parallel-group study will evaluate the safety and efficacy of the AB-101 topical hydrogel formulation when applied twice daily in participants with mild to moderate AD with or without secondary infections.
[0452] Participants will be screened within 14 days prior to the Day 1 study intervention dose to confirm their eligibility for the study. Screening visits and Day 1 visits may be combined. Treatment with the study intervention is administered via BID for up to 4 weeks (28 days), followed by a 1-week (7-day) follow-up, as described in the SoA. The total study duration for participants is approximately 5 weeks.
[0453] Children and adults aged 2 years or older with mild to moderate atopic dermatitis (as determined by the IGA scale) with or without secondary infection (as determined by the researchers and confirmed using the SIRS scale) will be enrolled in the study. The study consists of two cohorts, each with two subgroups. Cohort 1 will recruit 20 evaluable participants, and cohort 2 will recruit 40 evaluable participants. Participants will be randomly assigned in a 1:1 ratio to receive either the active substance or the carrier-controlled intervention.
[0454] Group 1: Mild to moderate Alzheimer's disease with secondary infections
[0455] Group 2: Mild or moderate AD without secondary infection
[0456] Once a participant agrees to participate and signs an informed consent form, he / she will enter the screening period. Participants with mild to moderate AD and a total body surface area (BSA) involvement (including the skin targetable area) ≥5%, who meet all inclusion criteria and no exclusion criteria, and who successfully complete the screening process, will be eligible for selection according to the IGA scale.
[0457] Once enrolled, participants will be randomly assigned to receive either AB-101 or a hydrogel carrier (2:1 ratio) for topical application to the affected AD area. The first dose will be administered at the clinic. Participants will be provided with a diary and instructions on how to apply the study intervention (BID, application interval). > Printed instructions (8 hours, maximum 28 days). Participants will return to the study clinic on days 4, 8, 15, 22, and 29 after screening for a total of 5 study efficacy assessment visits. All participants will also return on day 36 or 7 days after the last administration for follow-up studies.
[0458] Assessments of microbiological, IGA, EASI, SIRS, and BSA involvement rates will be performed on day 1 and at each efficacy study visit (days 4, 8, 15, 22, and 29). During these visits, lesion photographs will be taken at selected sites.
[0459] Participants in Group 1 will have their study intervention terminated and treatment ended if their AD is determined by the researchers to be clinically progressive in the skin involved in the AD in the target area used for the study.
[0460] Participants in Group 2 will have their study intervention terminated and treatment ended if their AD is judged by the researchers to be clinically progressive toward clinically evident infection of the skin in the target area used for the study.
[0461] Participants who terminated early in Group 1 and Group 2 will continue to participate in the study for 7 days to obtain follow-up data.
[0462] Assuming a dropout rate of 20%, the total of approximately 72 participants will be randomly divided into groups (24 in each group 1 and 48 in each group 2) to ensure that approximately 60 participants complete the course (20 in each group 1 and 40 in each group 2).
[0463] Researchers, participants, and the organizing research team will be unaware of the research intervention.
[0464] All primary and secondary endpoints will be achieved.
[0465] Polydispersity index analysis of Example 7-AB-101
[0466] To determine the PDI, an HPLC-UV method using gel permeation chromatography (GPC) and / or size exclusion chromatography (SEC) was developed for the analysis of this polymer. The polymer size distribution was calculated using the following equation: PDI = M w / M n M w It is the weight-average molecular weight, M n It is the number-average molecular weight.
[0467] Sample preparation: AB-101 was prepared by dividing the material into 5 mL aliquots and lyophilizing the samples overnight. The samples were then weighed and resuspended in water at a concentration of 5 mg / mL. The samples were then diluted in water before GPC-UV / CAD analysis for PDI determination. Details of the HPLC method are as follows:
[0468] • Column: Jordi Resolve column, 5μm (7.8mm ID x 300mm L), porosity:
[0469] HPLC conditions: isocratic: dimethylformamide (DMF)
[0470] • Flow rate: 0.7 mL / min
[0471] • Injection volume: 20 μL
[0472] Column temperature: 40℃
[0473] • Inspection: CAD
[0474] • Standard product: Polymethyl methacrylate (PMMA) EasiVials (Agilent)
[0475] Figure 14 and Figure 15 The gel permeation chromatograms of three PMMA standards being analyzed and tested are shown. The top line represents the yellow standard. The thicker middle line represents the red standard. The dashed bottom line represents the green standard. These standards were run at 2 mg / mL. The chromatograph displayed identifiable peaks, enabling PDI calculation. Figure 16 The chromatogram of AB-101 batch 01 at a concentration of 1.25 mg / mL is shown.
[0476] Polydispersity index calculation: Sample analysis of AB-101 batch 01 was performed using the developed method. (Log M) w Variation with retention time and Log M n A calibration curve is generated based on the change in retention time. The calibration curve is shown in... Figure 17A and 17B Using the calibration curve, PDI is able to calculate the M of AB-101 batch 01 based on the peak retention time. w and M n Values. The results are shown in Table 14.
[0477] Table 14
[0478] RT(min) <![CDATA[LogM W ]]> <![CDATA[M W ]]> <![CDATA[LogM n ]]> <![CDATA[M n ]]> 6.8 2.78 1.02 2.93 1.08 7.8 1.46 0.38 1.68 0.53 8.0 1.20 0.18 1.42 0.35 average value 0.53 average value 0.65 PDI 0.81
[0479] Lot 01 of AB-101 has a PDI of 0.81. This contrasts with the 0.9–1.2 PDI range of crofelemer disclosed in WO 2012 / 101088. The larger PDI of crofelemer indicates that through refining and fractionation processes, crofelemer exhibits greater inhomogeneity than AB-101 in terms of crosslinking, network formation, chain length, and branching.
[0480] Particle size analysis of Example 8-AB-101
[0481] Based on particle size analysis, AB-101 is a colloidal suspension. This inherently presents challenges for formulation because colloidal suspensions are inherently unstable. This is the first time a method has been shown to significantly improve the stability of hydrogels containing pharmaceutical-grade AB-101.
[0482] One of the main determinants of colloidal suspension stability is particle size distribution. As a natural plant extract, AB-101 exhibits a large particle size distribution. The particle size distribution of AB-101 was measured by the Particle Testing Authority (a division of Micromeritics Instrument Corporation) using a Saturn DigiSizer 5205 laser particle size analyzer. The results of the particle size distribution analysis are shown in... Figure 18 middle.
[0483] Pharmaceutical-grade AB-101 exhibits a very wide particle size distribution. The average particle size (μm) ranges from 0.040 μm to 150.335 μm. At the lower end of this range, containing 19.6% particles, the particle distribution spans from 0.040 μm to 0.142 μm. At the upper end of this range, containing 19.5% particles, the particle distribution spans from 2.249 μm to 150.335 μm. This is a very large particle distribution. Smaller, more uniform particles result in more stable products with a lower likelihood of separation. This wide colloidal particle distribution presents an inherent challenge to maintaining stability in hydrogels containing AB-101.
[0484] Zeta potential of Example 9-AB-101
[0485] The zeta potential is an important and easily measurable indicator of the stability of colloidal dispersions. The magnitude of the zeta potential indicates the degree of electrostatic repulsion between adjacent particles with similar charges in the dispersion. For sufficiently small molecules and particles, a high zeta potential will confer stability, meaning the solution or suspension will resist aggregation. When the potential is low, the attractive force may outweigh this repulsion, and the dispersion may coagulate, flocculate, and eventually solidify. Therefore, colloids with high zeta potentials (negative or positive) are electrostable, while colloids with low zeta potentials tend to coagulate or flocculate, as summarized in Table 15.
[0486] Table 15. Zeta potential and stability behavior
[0487] Zeta potential (mV) Stable behavior 0 to ±5 Rapid coagulation or flocculation ±10 to ±30 Initial instability ±30 to ±40 Medium stability ±40 to ±60 Good stability >61 Excellent stability
[0488] The zeta potential of the pharmaceutical-grade AB-101 extract was measured by the Particle Testing Authority using a NanoPlus HD zeta potential and nanoparticle analyzer. Figure 19 As shown, the zeta potential of AB-101 is 8.93 mV. Table 15 describes the properties of AB-101 as exhibiting behavior of "rapid flocculation to initial instability". Hydrogels formulated with pharmaceutical-grade AB-101 will form unstable hydrogels. This will result in formulations that fail to meet FDA requirements for providing a reliable drug delivery system.
[0489] Formulating physically stable hydrogels containing high concentrations of AB-101 is a significant achievement. The challenge lies in maintaining the drug bioactivity of the API, the full release of AB-101 from the hydrogel, the spreadability of the hydrogel, and simultaneously maintaining the target pH. The physical stability of the formulated hydrogel needs to prevent coagulation, flocculation, and solidification over time and at higher temperatures.
[0490] For the first time, an antiflocculating agent was used to formulate a novel, long-term physically stable hydrogel from pharmaceutical-grade AB-101. Table F shows the formulation of the AB-101-containing hydrogel stabilized using the antiflocculating agent. This formulation demonstrates, for the first time, a significant advancement in improving formulation stability by increasing the zeta potential, while maintaining the pharmaceutical and aesthetic properties of the AB-101 hydrogel.
[0491] As shown in Table F, the antiflocculating agents used are: disodium hydrogen phosphate heptahydrate, anhydrous sodium dihydrogen phosphate, and sodium hexametaphosphate. These antiflocculating agents release negatively charged phosphate groups, which function by electrostatically stabilizing particles adsorbed on the AB-101 surface and thus increasing the zeta potential. This causes the particles to repel each other, thereby minimizing coagulation and flocculation. The first two antiflocculating agents (disodium hydrogen phosphate heptahydrate and anhydrous sodium dihydrogen phosphate) belong to the phosphate family of antiflocculating agents, which provide immediate electrostatic stability by dissociating into immediately charged anions. Sodium hexametaphosphate is a long-chain polyphosphate that dissociates over time or upon exposure to higher temperatures, releasing phosphate groups, thus providing long-term electrostatic stability. Figure 20 The zeta potential measurements of the hydrogel formulation in Table F were depicted. Phosphate and hexametaphosphate raise the pH of the hydrogel to near neutral (≈6), which is ideal for skin wound healing applications.
[0492] By Figure 19 The zeta potential of the extract of the Chinese medicine AB-101 and such Figure 20 The comparison of the zeta potentials of the AB-101 hydrogel formulations in Table F shows an improvement in stability.
[0493] Figure 20 The zeta potential of the AB-101 hydrogel containing the antiflocculator shown in Table F is -59.92 mV. This represents a significant improvement compared to the 8.93 mV zeta potential of the AB-101 drug extract. Table 15 characterizes the properties of the AB-101 hydrogel as exhibiting "good stability" behavior. This hydrogel formulation will produce FDA-compliant formulations to provide reliable drug delivery.
Claims
1. A hydrogel formulation for treating bacterial skin infections, comprising the following components: Filtered latex of Peruvian croton, glycerin, methylparaben, propylparaben, water, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate, sodium hexametaphosphate, medium-chain triglycerides, SEPINEO™ P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80). The amount of filtered latex from the Peruvian croton oil mentioned above is 10 wt% to 75 wt%. The amount of glycerol is 1 wt% to 5 wt%; The amount of methylparaben is 0.05 wt% to 0.5 wt%; The amount of propylparaben is 0.005 wt% to 0.05 wt%; The amount of water therein is 20 wt% to 80 wt%; The amount of the disodium hydrogen phosphate heptahydrate is 1 wt% to 3 wt%; The amount of sodium dihydrogen phosphate therein is 0.1% to 0.4%; The amount of sodium hexametaphosphate is from 0.005 wt% to 0.02 wt%. The amount of the medium-chain triglyceride is from 1 wt% to 6 wt%. The amount of SEPINEO™ P 600 (acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80) is 0.5 wt% to 10 wt%.
2. The hydrogel formulation according to claim 1, wherein the filtered latex of Peruvian croton is Müll.Arg. filtered latex of Peruvian croton.
3. The hydrogel formulation according to claim 1, wherein the amount of filtered latex of Peruvian croton is 30 wt% to 50 wt%.
4. The hydrogel formulation according to claim 1, wherein the amount of filtered latex of Peruvian croton is 36 wt% to 44 wt%.
5. Use of the hydrogel formulation of claim 1 in the preparation of a medicament for treating skin conditions, wherein the skin conditions are selected from those caused by Staphylococcus aureus infection, characterized in that... The drug is used for topical application of a therapeutically effective amount of the hydrogel formulation.
6. The use according to claim 5, wherein the skin condition is selected from the group consisting of skin conditions caused by methicillin-resistant Staphylococcus aureus (MRSA) infection and skin conditions caused by mupirocin-resistant MRSA infection.
7. The use according to claim 5, wherein the skin condition is selected from atopic dermatitis caused by Staphylococcus aureus infection.
8. The use according to claim 5, wherein the skin condition is selected from the group consisting of atopic dermatitis caused by methicillin-resistant Staphylococcus aureus (MRSA) infection and atopic dermatitis caused by mupirocin-resistant MRSA infection.
9. The use according to claim 5, wherein the application continues until the skin condition is treated.
10. The use according to claim 5, wherein the topical application is applied directly to the skin condition.
11. The use according to claim 5, wherein the treatment continues until the skin condition is treated.
Citation Information
Patent Citations
Compositions comprising cromoglicic acid for the treatment of dermatitis
US20190240193A1
Method of treating emesis and itch
US7883727B1
Method for assembling shell segments for forming tower sections of a hybrid wind turbine tower
WO2012101088A1
Topical croton lechleri compositions for the treatment of acute bacterial skin or skin structure infection
WO2020191384A1
